<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pre‐ and postsurgical medical therapy for endometriosis surgery - Chen, I - 2020 | Cochrane Library</title> <meta content="Pre‐ and postsurgical medical therapy for endometriosis surgery - Chen, I - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003678.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pre‐ and postsurgical medical therapy for endometriosis surgery - Chen, I - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003678.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003678.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pre‐ and postsurgical medical therapy for endometriosis surgery" name="citation_title"/> <meta content="Innie Chen" name="citation_author"/> <meta content="ichen@toh.on.ca" name="citation_author_email"/> <meta content="Veerle B Veth" name="citation_author"/> <meta content="Máxima Medical Center" name="citation_author_institution"/> <meta content="Abdul J Choudhry" name="citation_author"/> <meta content="Ottawa Hospital Research Institute" name="citation_author_institution"/> <meta content="Ally Murji" name="citation_author"/> <meta content="Mount Sinai Hospital, University of Toronto" name="citation_author_institution"/> <meta content="Andrew Zakhari" name="citation_author"/> <meta content="McGill University" name="citation_author_institution"/> <meta content="Amanda Y Black" name="citation_author"/> <meta content="Carmina Agarpao" name="citation_author"/> <meta content="Ottawa Hospital Research Institute" name="citation_author_institution"/> <meta content="Jacques WM Maas" name="citation_author"/> <meta content="Máxima Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD003678.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003678.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003678.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003678.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Chemotherapy, Adjuvant [methods]; Combined Modality Therapy [methods]; Contraceptive Agents, Female [*therapeutic use]; Endometriosis [*drug therapy, surgery]; Estrogen Antagonists [*therapeutic use]; Gonadotropin-Releasing Hormone [antagonists &amp; inhibitors]; Pain Measurement; Pelvic Pain [prevention &amp; control, therapy]; Placebos [therapeutic use]; Postoperative Care [methods]; Pregnancy Rate; Preoperative Care [methods]; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention [*methods]; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003678.pub3&amp;doi=10.1002/14651858.CD003678.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="6nHUP32m";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003678\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003678\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","th","ms","ja","fa","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003678.pub3",title:"Pre\\u2010 and postsurgical medical therapy for endometriosis surgery",firstPublishedDate:"Nov 18, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6nHUP32m&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003678.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003678.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003678.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003678.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003678.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003678.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003678.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003678.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003678.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003678.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6704 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003678.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-sec-0103"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-sec-0097"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/appendices#CD003678-sec-0108"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/supinfo/CD003678StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/supinfo/CD003678StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pre‐ and postsurgical medical therapy for endometriosis surgery</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#CD003678-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Innie Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#CD003678-cr-0005">Veerle B Veth</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#CD003678-cr-0006">Abdul J Choudhry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#CD003678-cr-0007">Ally Murji</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#CD003678-cr-0008">Andrew Zakhari</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#CD003678-cr-0009">Amanda Y Black</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#CD003678-cr-0010">Carmina Agarpao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information#CD003678-cr-0011">Jacques WM Maas</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information/en#CD003678-sec-0120">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003678.pub3">https://doi.org/10.1002/14651858.CD003678.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003678-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003678-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003678-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003678-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003678-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD003678-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003678-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003678-abs-0001" lang="en"> <section id="CD003678-sec-0001"> <h3 class="title" id="CD003678-sec-0001">Background</h3> <p>Endometriosis is a common gynaecological condition affecting 10% to 15% of reproductive‐age women and may cause dyspareunia, dysmenorrhoea, and infertility. One treatment strategy is combining surgery and medical therapy to reduce the recurrence of endometriosis. Though the combination of surgery and medical therapy appears to be beneficial, there is a lack of clarity about the appropriate timing of when medical therapy should be used in relation with surgery, that is, before, after, or both before and after surgery, to maximize treatment response. </p> </section> <section id="CD003678-sec-0002"> <h3 class="title" id="CD003678-sec-0002">Objectives</h3> <p>To determine the effectiveness of medical therapies for hormonal suppression before, after, or both before and after surgery for endometriosis for improving painful symptoms, reducing disease recurrence, and increasing pregnancy rates. </p> </section> <section id="CD003678-sec-0003"> <h3 class="title" id="CD003678-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, and two trials registers in November 2019 together with reference checking and contact with study authors and experts in the field to identify additional studies. </p> </section> <section id="CD003678-sec-0004"> <h3 class="title" id="CD003678-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) which compared medical therapies for hormonal suppression before, after, or before and after, therapeutic surgery for endometriosis. </p> </section> <section id="CD003678-sec-0005"> <h3 class="title" id="CD003678-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed risk of bias. Where possible, we combined data using risk ratio (RR), standardized mean difference or mean difference (MD) and 95% confidence intervals (CI). Primary outcomes were: painful symptoms of endometriosis as measured by a visual analogue scale (VAS) of pain, other validated scales or dichotomous outcomes; and recurrence of disease as evidenced by EEC (Endoscopic Endometriosis Classification), rAFS (revised American Fertility Society), or rASRM (revised American Society for Reproductive Medicine) scores at second‐look laparoscopy. </p> </section> <section id="CD003678-sec-0006"> <h3 class="title" id="CD003678-sec-0006">Main results</h3> <p>We included 25 trials with 3378 women with endometriosis. We used the term "surgery alone" to refer to placebo or no medical therapy. </p> <p><b>Presurgical medical therapy compared with placebo or no medical therapy</b> </p> <p>Compared to surgery alone, we are uncertain if presurgical medical hormonal suppression reduces pain recurrence at 12 months or less (dichotomous) (RR 1.10, 95% CI 0.72 to 1.66; 1 RCT, n = 262; very low‐quality evidence) or whether it reduces disease recurrence at 12 months – total (AFS score) (MD –9.6, 95% CI –11.42 to –7.78; 1 RCT, n = 80; very low‐quality evidence). </p> <p>We are uncertain if presurgical medical hormonal suppression decreases disease recurrence at 12 months or less (EEC stage) compared to surgery alone (RR 1.11, 95% CI 0.86 to 1.43; 1 RCT, n = 262; very low‐quality evidence). We are uncertain if presurgical medical hormonal suppression improves pregnancy rates compared to surgery alone (RR 1.18, 95% CI 0.97 to 1.45; 1 RCT, n = 262; very low‐quality evidence). No trials reported pelvic pain at 12 months or less (continuous) or disease recurrence at 12 months or less. </p> <p><b>Postsurgical medical therapy compared with placebo or no medical therapy</b> </p> <p>We are uncertain about the improvement observed in pelvic pain at 12 months or less (continuous) between postsurgical medical hormonal suppression and surgery alone (SMD ‐0.79, 95% CI ‐1.02 to ‐0.56; 3 RCTs, n = 340; I<sup>2</sup> = 91%; very low‐quality evidence). </p> <p>Compared to surgery alone, postsurgical medical therapy may decrease pain recurrence at 12 months or less (dichotomous) (RR 0.70, 95% CI 0.52 to 0.94; 5 RCTs, n = 657; I<sup>2</sup> = 0%; low‐quality evidence). </p> <p>We are uncertain if postsurgical medical hormonal suppression improves disease recurrence at 12 months – total (AFS score) compared to surgery alone (MD –2.29, 95% CI –4.01 to –0.57; 1 RCT, n = 51; very low‐quality evidence). </p> <p>Disease recurrence at 12 months or less may be reduced with postsurgical medical hormonal suppression compared to surgery alone (RR 0.30, 95% CI 0.17 to 0.54; 4 RCTs, n = 433; I<sup>2</sup> = 58%; low‐quality evidence). </p> <p>We are uncertain if postsurgical medical hormonal suppression improves disease recurrence at 12 months or less (EEC stage) (RR 0.88, 95% CI 0.67 to 1.15; 1 RCT, n = 285; very low‐quality evidence). </p> <p>Pregnancy rate is probably increased with postsurgical medical hormonal suppression compared to surgery alone (RR 1.19, 95% CI 1.02 to 1.38; 11 RCTs, n = 955; I<sup>2</sup> = 27%; moderate‐quality evidence). </p> <p><b>Pre‐ and postsurgical medical therapy compared with surgery alone or surgery and placebo</b> </p> <p>There were no trials identified in the search for this comparison.</p> <p><b>Presurgical medical therapy compared with postsurgical medical therapy</b> </p> <p>We are uncertain about the difference in pain recurrence at 12 months or less (dichotomous) between postsurgical and presurgical medical hormonal suppression therapy (RR 1.40, 95% CI 0.95 to 2.07; 2 RCTs, n = 326; I<sup>2</sup> = 2%; low‐quality evidence). </p> <p>We are uncertain about the difference in disease recurrence at 12 months or less (EEC stage) between postsurgical and presurgical medical hormonal suppression therapy (RR 1.26, 95% CI 0.97 to 1.65; 1 RCT, n = 273; very low‐quality evidence). </p> <p>We are uncertain about the difference in pregnancy rate between postsurgical and presurgical medical hormonal suppression therapy (RR 1.08, 95% CI 0.90 to 1.30; 1 RCT, n = 273; very low‐quality evidence). </p> <p>No trials reported pelvic pain at 12 months or less (continuous), disease recurrence at 12 months – total (AFS score) or disease recurrence at 12 months or less (dichotomous). </p> <p><b>Postsurgical medical therapy compared with pre‐ and postsurgical medical therapy</b> </p> <p>There were no trials identified in the search for this comparison.</p> <p><b>Serious adverse effects for medical therapies reviewed</b> </p> <p>There was insufficient evidence to reach a conclusion regarding serious adverse effects, as no studies reported data suitable for analysis. </p> </section> <section id="CD003678-sec-0007"> <h3 class="title" id="CD003678-sec-0007">Authors' conclusions</h3> <p>Our results indicate that the data about the efficacy of medical therapy for endometriosis are inconclusive, related to the timing of hormonal suppression therapy relative to surgery for endometriosis. In our various comparisons of the timing of hormonal suppression therapy, women who receive postsurgical medical therapy compared with no medical therapy or placebo may experience benefit in terms of pain recurrence, disease recurrence, and pregnancy. There is insufficient evidence regarding hormonal suppression therapy at other time points in relation to surgery for women with endometriosis. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003678-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003678-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003678-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003678-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003678-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD003678-abs-0013">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003678-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003678-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD003678-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003678-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003678-abs-0002" lang="en"> <h3>Pre‐ and postsurgical medical therapy for endometriosis surgery</h3> <p><b>Review question</b> </p> <p>What are the effects of medical hormonal suppression therapies administered before or after (or both) surgical treatment of endometriosis compared to surgery alone or medical therapy before or after (or both) surgery? </p> <p><b>Background</b> </p> <p>In endometriosis, tissue like the lining of the womb starts to grow in other places, such as the ovaries and fallopian tubes. It affects 10% to 15% of reproductive‐age women, and may cause pain in the lower tummy (pelvic pain) or back (which usually worsen during a woman's periods), painful sexual intercourse, and difficulty becoming pregnant. </p> <p>Treatment to lower the levels of reproductive hormones (called medical hormonal suppression therapy) is common to reduce the size of endometrial tissue along with surgery to cut it away. Medical therapy can reduce pain or its reappearance, reduce disease recurrence (the chance of it coming back), and improve pregnancy rate. Potential benefits of medication may depend on whether it is given before or after surgery for endometriosis, but evidence is not clear. </p> <p><b>Study characteristics</b> </p> <p>We found 25 randomized controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) with 3378 women who underwent surgery with or without medical therapy. We used the term "surgery alone" to refer to placebo or no medical therapy. The evidence is current to November 2019. </p> <p><b>Key results</b> </p> <p>Medical therapy showed variable effects on pain, reappearance of pain or disease, and pregnancy rate when used before or after surgery for endometriosis. However, for outcomes disease recurrence and pregnancy, it may be most effective after surgery versus surgery alone compared to other comparisons reviewed. </p> <p><b>Medical therapy before surgery compared with placebo or no medical therapy</b> </p> <p>Very weak evidence suggests that if pelvic pain recurrence at 12 months or less is 24% among women having surgery alone, the chance with medical therapy before surgery would be between 17% and 40%. </p> <p>Very weak evidence suggests that if disease recurrence at 12 months or less is 45% among women having surgery alone, the chance with medical therapy before surgery would be between 39% and 65%. </p> <p>Very weak evidence suggests that if pregnancy rate is 58% among women having surgery alone, the chance with medical therapy before surgery would be between 53% and 79%. </p> <p><b>Medical therapy after surgery compared with placebo or no medical therapy</b> </p> <p>Weak evidence suggests that if pain recurrence at 12 months or less is 26% among women having surgery alone, the chance with medical therapy after surgery would be between 13% and 24%. </p> <p>Weak evidence suggests that if disease recurrence at 12 months or less is 17% among women having surgery alone, the chance with medical therapy after surgery would be between 3% and 9%. </p> <p>Very weak evidence suggests that if disease recurrence at 12 months or less (different classification used) is 45% among women having surgery alone, the chance with medical therapy after surgery would be between 30% and 52%. </p> <p>Moderate‐quality evidence suggests that if pregnancy rate is 34% among women having surgery alone, the chance with medical therapy after surgery would be between 35% and 48%. </p> <p><b>Medical therapy before surgery compared with medical therapy after surgery</b> </p> <p>Weak evidence suggests that if pelvic pain recurrence at 12 months or less is 20% among women having medical therapy after surgery, the chance with medical therapy before surgery would be between 19% and 41%. </p> <p>Very weak evidence suggests that if disease recurrence at 12 months or less is 40% among women having medical therapy after surgery, the chance with medical therapy before surgery would be between 39% and 66%. </p> <p>Very weak evidence suggests that if pregnancy rate is 60% among women having medical therapy after surgery, the chance with medical therapy before surgery would be between 54% and 78%. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence was of very low to moderate quality.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003678-sec-0103" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003678-sec-0103"></div> <h3 class="title" id="CD003678-sec-0104">Implications for practice</h3> <section id="CD003678-sec-0104"> <p>Our results indicate that the efficacy of medical therapy for endometriosis related to the timing of therapy relative to surgery for endometriosis is inconclusive. In our various comparisons of the timing for therapy, we have found some evidence to indicate that postsurgical medical therapy compared with no medical therapy after surgery may be beneficial with respect to pain recurrence, disease recurrence and pregnancy. The evidence on pain outcomes is inconclusive. There is insufficient evidence regarding medical therapy at other time points in relation to surgery for women with endometriosis. </p> </section> <h3 class="title" id="CD003678-sec-0105">Implications for research</h3> <section id="CD003678-sec-0105"> <p>Our review is unable to provide conclusive evidence for the appropriate time of use of medical therapy relative to surgery, primarily due to few studies for each comparison and small sample size for most of included studies. As this is not a heavily researched area, a number of factors need special attention for any future research on this topic. </p> <p>Research conducted to assess the effects of medical therapy pre or postsurgery for endometriosis is associated with many difficulties. Not many women are likely to consent to undergo second‐look laparoscopy, just to assess the results of previous treatment modalities. Hence, recruiting large numbers of participants for randomized trials is difficult. Women with subfertility due to endometriosis may also not accept treatment that may improve pain and other symptoms but reduces or delays their chance of conceiving. Despite these difficulties, it would be valuable to have adequately powered trials to determine if there is a significant benefit in adjunctive medical therapy before or after surgery for endometriosis. </p> <p>Due to nature of hormonal suppression medical therapy and its associated therapeutic and adverse effects, which would be obvious to both the participant and outcome assessor, maintaining blinding is difficult. But still blinded outcome assessment is possible and is highly desirable. </p> <p>A key missing limitation is that although multiple studies were included in each comparison, they did not report the same outcome. Even if they reported the same outcome (e.g. pain), they used different presentations (pelvic pain, dyspareunia, dysmenorrhea), scales (continuous or dichotomous), or measures of occurrence (presence, continuation, recurrence), which makes trial interpretation and evidence synthesis difficult. Due to heterogeneity of the outcome measures, a meta‐analysis was possible only with a small number of studies, with a small number of participants for each outcome measure. A core outcome set for endometriosis‐associated outcome measures has been developed (<a href="./references#CD003678-bbs2-0041" title="DuffyJMN , HirschM , VercoeM , AbbottJ , BarkerC , ColluraB , et al. A core outcome set for future endometriosis research: an international consensus development study. BJOG: An International Journal of Obstetrics &amp; Gynaecology2020;127:967– 974.">Duffy 2020</a>) and new trials should consider using it to provide more comparable data for future research. </p> <p>Despite these difficulties, it would be valuable to have well‐designed, adequately powered, and well‐conducted trials to determine if there is a significant benefit in adjunctive medical therapy before or after surgery for endometriosis. Data to quantify the number and degree of adverse events experienced as a result of medical therapy would enable better assessment of the comparative benefits and harms of medical therapy. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003678-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003678-sec-0008"></div> <div class="table" id="CD003678-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Presurgical medical therapy compared with placebo or no medical therapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Presurgical medical therapy compared with placebo or no medical therapy for endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women having endometriosis surgery </p> <p><b>Intervention:</b> presurgical medical therapy </p> <p><b>Comparison:</b> placebo or no medical therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no medical therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Presurgical medical therapies</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> (continuous) </p> <p>Pelvic pain ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain recurrence</b> (dichotomous) </p> <p>Pain recurrence ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>265 per 1000</b><br/>(174 to 400) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/>(0.72 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence at 3 months</b> – total (AFS score) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean recurrence – AFS score – total AFS in the control groups was 44.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean recurrence – AFS score – total AFS in the intervention groups was<br/><b>9.6 lower</b><br/>(11.42 to 7.78 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence ≤ 12 months</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence ≤ 12 months (EEC stage)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>453 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>502 per 1000</b> </p> <p>(389 to 647)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> (0.86 to 1.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy rate</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>547 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>646 per 1000</b><br/>(531 to 794) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b><br/>(0.97 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AFS:</b> American Fertility Society; <b>CI:</b> confidence interval; <b>EEC:</b> Endoscopic Endometriosis Classification; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for serious risk of bias – no blinding and trial lacked details on allocation concealment.<br/><sup>b</sup>Downgraded twice for very serious imprecision – evidence based on a single trial, wide confidence interval, small number of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003678-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Postsurgical medical therapy compared with placebo or no medical therapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Postsurgical medical therapy compared with placebo or no medical therapy for endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women having endometriosis surgery </p> <p><b>Intervention:</b> postsurgical medical therapy </p> <p><b>Comparison:</b> placebo or no medical therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no medical therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Postsurgical medical therapies</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> (continuous) </p> <p>Pelvic pain ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pelvic pain score ≤ 12 months in the ranged across control groups from 0.35 to 7 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pelvic pain score ≤ 12 months in the intervention groups was<br/><b>0.79 lower</b><br/>(1.02 to 0.56 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain recurrence</b> (dichotomous) </p> <p>Pain recurrence ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>255 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> </p> <p>(132 to 239)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b><br/>(0.52 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>657<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence at 12 months</b> – <b>total (AFS score)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean recurrence – AFS score – total AFS in the control groups was 3.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean recurrence – AFS score – total AFS in the intervention groups was<br/><b>2.29 lower</b><br/>(4.01 to 0.57 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence ≤ 12 months</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> </p> <p>(29 to 92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.30</b><br/>(0.17 to 0.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence</b> </p> <p><b>≤ 12 months (EEC stage)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>453 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>398 per 1000</b> </p> <p>(303 to 520)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> (0.67 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy rate</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>409 per 1000</b> </p> <p>(351 to 475)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b><br/>(1.02 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>955</p> <p>(11 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AFS:</b> American Fertility Society; <b>CI:</b> confidence interval; <b>EEC:</b> Endoscopic Endometriosis Classification; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for risk of bias – there are inadequate details on blinding and attrition.<br/><sup>b</sup>Downgraded twice for very serious inconsistency – considerable heterogeneity.<br/><sup>c</sup>Downgraded once for imprecision – small number of events </p> <p><sup>d</sup>Downgraded twice for very serious imprecision – small number of events/evidence is based on a single study.<br/><sup>e</sup>Downgraded once for risk of bias – the trial lacked details on allocation concealment and randomization..<br/><sup>f</sup>Downgraded once for inconsistency – considerable heterogeneity. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003678-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Presurgical medical therapy compared with postsurgical medical therapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Presurgical medical therapy compared with postsurgical medical therapy for endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women having endometriosis surgery </p> <p><b>Intervention:</b> presurgical medical therapy </p> <p><b>Comparison:</b> postsurgical medical therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Postsurgical medical therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Presurgical medical therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> (continuous) </p> <p>Pelvic pain ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain recurrence</b> (dichotomous) </p> <p>Pain recurrence ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>279 per 1000</b> </p> <p>(189 to 412)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b><br/>(0.95 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence at 12 months</b> –<b>total (AFS score)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence ≤ 12 months</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence ≤ 12 months (EEC stage)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>399 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>502 per 1000</b> </p> <p>(387 to 658)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b><br/>(0.97 to 1.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy rate</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>601 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>649 per 1000</b> </p> <p>(541 to 782)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/>(0.90 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AFS:</b> American Fertility Society; <b>CI:</b> confidence interval; <b>EEC:</b> Endoscopic Endometriosis Classification; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for serious risk of bias – no blinding and trial lacked details on allocation concealment.<br/><br/><sup>b</sup>Downgraded twice for very serious imprecision – evidence based on a single trial, wide confidence interval, and small number of events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003678-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003678-sec-0009"></div> <section id="CD003678-sec-0010"> <h3 class="title" id="CD003678-sec-0010">Description of the condition</h3> <p>Endometriosis is a chronic inflammatory condition characterized by the presence of endometrial glands and stroma outside of the uterine cavity and diagnosed by surgery (<a href="./references#CD003678-bbs2-0051" title="LeylandN , CasperR , LabergeP , SinghSS , AllenL , ArendasK , et al. Endometriosis: diagnosis and management. Journal of Obstetrics and Gynaecology Canada2010;32(7):S1-3.">Leyland 2010</a>; <a href="./references#CD003678-bbs2-0033" title="Acien Pedro, Velasco Irene. Endometriosis: a disease that remains enigmatic. ISRN Obstetrics and Gynecology2013;2013:1-12.">Acien 2013</a>). It affects 10% to 15% of reproductive‐age women (<a href="./references#CD003678-bbs2-0053" title="MacerML , TaylorHS . Endometriosis and infertility. A review of the pathogenesis and treatment of endometriosis-associated infertility. Obstetrics and Gynecology Clinics of North America2012;39(4):535-49.">Macer 2012</a>; <a href="./references#CD003678-bbs2-0054" title="MissmerSA , CramerDW . The epidemiology of endometriosis. Obstetrics and Gynecology Clinics of North America2003;30(1):1-19, vii.">Missmer 2003</a>), and may cause dyspareunia, dysmenorrhoea, and infertility. As 30% to 50% of women with endometriosis may have difficulty conceiving (<a href="./references#CD003678-bbs2-0053" title="MacerML , TaylorHS . Endometriosis and infertility. A review of the pathogenesis and treatment of endometriosis-associated infertility. Obstetrics and Gynecology Clinics of North America2012;39(4):535-49.">Macer 2012</a>), more women with endometriosis are achieving pregnancy through assisted reproductive technology (ART) (<a href="./references#CD003678-bbs2-0057" title="StephanssonO , KielerH , GranathF , FalconerH . Endometriosis, assisted reproduction technology, and risk of adverse pregnancy outcome. Human Reproduction2009;24(9):2341-7.">Stephansson 2009</a>). </p> <p>Pathogenesis of endometriosis remain poorly understood and has been attributed to retrograde menstruation implantation, Mullerian remnant abnormalities, coelomic metaplasia, angiogenetic/lymphogenetic spread, metaplasia theory, and genetic/epigenetic theory (<a href="./references#CD003678-bbs2-0049" title="KoninckxPR , Ussia A AdamyanL , WattiezA , GomelV , MartinDC . Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertility and Sterility2019;111(2):327-40.">Koninckx 2019</a>; <a href="./references#CD003678-bbs2-0060" title="VercelliniP , ViganoP , SomiglianaE , FedeleL . Endometriosis: pathogenesis and treatment. National Review of Endocrinology2014;10:261-75.">Vercellini 2014</a>). Clinical examination has low sensitivity and specificity for diagnosis of endometriosis, and laparoscopy remain the gold standard for diagnosis; however, recent studies looks promising for new sonographic and magnetic resonance imaging (MRI) techniques (<a href="./references#CD003678-bbs2-0035" title="BazotM , DaraiE . Diagnosis of deep endometriosis: clinical examination, ultrasonography, magnetic resonance imaging, and other techniques. Fertility and Sterility2017;108(6):886-94.">Bazot 2017</a>). </p> <p>A number of classification systems for endometriosis have been developed, with the revised American Society for Reproductive Medicine (r‐ASRM) classification being the best‐known, originally developed in 1985 and revised in 1997 (<a href="./references#CD003678-bbs2-0034" title="American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertility and Sterility1997;67(5):817-21.">ASRM 1997</a>; <a href="./references#CD003678-bbs2-0047" title="JohnsonNP , HummelshojL , AdamsonGD , KecksteinJ , TaylorHS , Abrao MauricioS , et al. World endometriosis society consensus on the classification of endometriosis. Human Reproduction2017;32(2):315-24.">Johnson 2017</a>). However, classification systems have been criticized by women and care providers due to their poor correlation with disease symptoms and predictive prognosis (<a href="./references#CD003678-bbs2-0047" title="JohnsonNP , HummelshojL , AdamsonGD , KecksteinJ , TaylorHS , Abrao MauricioS , et al. World endometriosis society consensus on the classification of endometriosis. Human Reproduction2017;32(2):315-24.">Johnson 2017</a>). </p> </section> <section id="CD003678-sec-0011"> <h3 class="title" id="CD003678-sec-0011">Description of the intervention</h3> <p>As the presentation for endometriosis encompass two diverse spectra (i.e. pain and infertility), the choice of management strategies, whether medical or surgical, are made accordingly. For the treatment of pain, the choice between two alternatives is influenced by presence or absence of large endometriomas, ureteral/bowel stenosis, and desire for spontaneous pregnancy (<a href="./references#CD003678-bbs2-0060" title="VercelliniP , ViganoP , SomiglianaE , FedeleL . Endometriosis: pathogenesis and treatment. National Review of Endocrinology2014;10:261-75.">Vercellini 2014</a>). </p> <p>Effect of surgery on pain is usually satisfactory but mostly temporary (<a href="./references#CD003678-bbs2-0060" title="VercelliniP , ViganoP , SomiglianaE , FedeleL . Endometriosis: pathogenesis and treatment. National Review of Endocrinology2014;10:261-75.">Vercellini 2014</a>), and has been reserved for women in whom medical therapy has failed or women with ovarian endometriomas greater than 3 cm in diameter (or both) (<a href="./references#CD003678-bbs2-0051" title="LeylandN , CasperR , LabergeP , SinghSS , AllenL , ArendasK , et al. Endometriosis: diagnosis and management. Journal of Obstetrics and Gynaecology Canada2010;32(7):S1-3.">Leyland 2010</a>). Laparoscopic treatment for minimal or mild endometriosis improves pregnancy; however, it's controversial for deeply infiltrating endometriosis. </p> <p>Over the time, there has been increasing interest in combining medical and surgical therapy to reduce recurrence of endometriosis. The presurgical use of progestin, GnRHas, or danazol (an androgen receptor agonist) may decrease the extent of endometriosis and the size of endometriomas (ovarian endometriosis) making complete removal of endometriosis easier during laparoscopic surgery and increasing subsequent pregnancy rates (<a href="./references#CD003678-bbs2-0036" title="BedaiwyMA , AllaireC , AlfarajS . Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertility and Sterility2017;107(3):537-48.">Bedaiwy 2017</a>; <a href="./references#CD003678-bbs2-0039" title="DonnezJ , Lemaire-RubbersM , KaramanY , Nisolle-PochetM , Casanas-RouxF . Combined (hormonal and microsurgical) therapy in infertile women with endometriosis. Fertility and Sterility1987;48(2):239-42.">Donnez 1987</a>; <a href="./references#CD003678-bbs2-0040" title="DonnezJ , PirardC , SmetsM , JadoulP , SquiffletJ . Surgical management of endometriosis. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2004;18(2):329-48.">Donnez 2004</a>; <a href="./references#CD003678-bbs2-0044" title="HemmingsR . Combined treatment of endometriosis, GnRH agonists and laparoscopic surgery. Journal of Reproductive Medicine1998;43 Suppl(2):316-20.">Hemmings 1998</a>). However, possible disadvantages of presurgical medical therapy, especially with danazol or GnRHas, are the adverse effects associated with these medications (e.g. hot flushes and vaginal dryness), which may influence women's willingness to use the therapy, and result only in a delay of surgery. However, benefits include inducing suppression of lesions that cannot be surgically removed, and reducing the risk of recurrence of endometriosis as a result of surgery (<a href="./references#CD003678-bbs2-0048" title="KettelLM , MurphyAA . Combination medical and surgical therapy for infertile patients with endometriosis. Obstetrics and Gynecology Clinics of North America1989;16(1):167-77.">Kettel 1989</a>; <a href="./references#CD003678-bbs2-0058" title="ThomasEJ . Combining medical and surgical treatment for endometriosis: the best of both worlds?British Journal of Obstetrics and Gynaecology1992;99 Suppl 7:5-8.">Thomas 1992</a>). Similarly, postsurgical medical therapy to prevent recurrence of endometriomas has been recommended and is gaining popularity (<a href="./references#CD003678-bbs2-0059" title="VercelliniP , MatteisSD , SomiglianaE , BuggioL , FrattaruoloMP , FedeleL . Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis. Acta Obstetricia et Gynecologica Scandinavica2013;92(1):8-16.">Vercellini 2013</a>). But there is hardly any information about comparison between presurgical and postsurgical medical therapy for the treatment of endometriosis. </p> </section> <section id="CD003678-sec-0012"> <h3 class="title" id="CD003678-sec-0012">How the intervention might work</h3> <p>For medical management of pain associated with endometriosis, combined hormonal contraceptive or progestins (e.g. dienogest) are recommended as first‐line therapy, while gonadotropin‐releasing hormone agonists (GnRHa) (with hormone therapy (HT) add back to control adverse events) or levonorgestrel‐releasing intrauterine system (LNG‐IUS) are recommended as second‐line therapeutic options (<a href="./references#CD003678-bbs2-0036" title="BedaiwyMA , AllaireC , AlfarajS . Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertility and Sterility2017;107(3):537-48.">Bedaiwy 2017</a>; <a href="./references#CD003678-bbs2-0051" title="LeylandN , CasperR , LabergeP , SinghSS , AllenL , ArendasK , et al. Endometriosis: diagnosis and management. Journal of Obstetrics and Gynaecology Canada2010;32(7):S1-3.">Leyland 2010</a>). Regarding mechanism of action suppression of endogenous oestrogen production is important for the successful treatment of endometriosis‐associated pain. Suppression of ovulation by hormonal contraceptives will in turn induce amenorrhoea, thereby creating a relatively hypo‐oestrogenic environment that will inhibit ectopic endometrial growth and prevent disease progression. Studies have also shown that progestins have both an anovulatory and an antiproliferative effect, while inhibiting the secretion of cytokines in the stroma of endometrial cells. Thus, inhibiting the growth of endometriotic tissue by inducing decidualization followed by atrophy of the endometriotic implants. Prolonged treatment with GnRHa leads to downregulation of the pituitary gonadotropin‐releasing hormone (GnRH) receptor with a subsequent decrease in pituitary secretion of luteinizing hormone (LH) and follicle‐stimulating hormone (FSH). This will in turn suppress ovarian follicular growth and ovulation, resulting in very low levels of circulating oestradiol and progesterone. Within one month of GnRH use, the circulating oestradiol concentrations will be in the menopausal range. Like dienogest, GnRHa may have direct effects on the endometrium and endometriotic implants (<a href="./references#CD003678-bbs2-0036" title="BedaiwyMA , AllaireC , AlfarajS . Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertility and Sterility2017;107(3):537-48.">Bedaiwy 2017</a>). GnRHa suppression with HT add‐back before in vitro fertilization (IVF) is also associated with improved pregnancy rate (<a href="./references#CD003678-bbs2-0051" title="LeylandN , CasperR , LabergeP , SinghSS , AllenL , ArendasK , et al. Endometriosis: diagnosis and management. Journal of Obstetrics and Gynaecology Canada2010;32(7):S1-3.">Leyland 2010</a>). However, we consider that LNG‐IUSs do not meet the inclusion requirement for systemic hormonal suppression, and, therefore, excluded them. </p> <p>While presurgical medical therapy is generally used to treat existing endometriosis lesions, postsurgical medical therapy is generally used to prevent recurrence of endometriosis after surgical removal. Whether the hormonal medical therapy is used before, after or both before and after the surgery it is expected to improve the outcome, as compared to surgery alone. </p> </section> <section id="CD003678-sec-0013"> <h3 class="title" id="CD003678-sec-0013">Why it is important to do this review</h3> <p>A large number of studies and reviews compared various medical therapies for the treatment of endometriosis, with or without surgery and have clarified advantages and disadvantages in terms of efficacy, adverse events, and cost (<a href="./references#CD003678-bbs2-0037" title="BrownJ , FarquharC . Endometriosis: an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD009590. [DOI: 10.1002/14651858.CD009590.pub2]">Brown 2014</a>; <a href="./references#CD003678-bbs2-0060" title="VercelliniP , ViganoP , SomiglianaE , FedeleL . Endometriosis: pathogenesis and treatment. National Review of Endocrinology2014;10:261-75.">Vercellini 2014</a>). Though the combination of surgery and medical therapy appears to be beneficial, the evidence is not conclusive (<a href="./references#CD003678-bbs2-0056" title="SomiglianaE , BusnelliA , BenagliaL , ViganaP , LeonardiM , PaffoniA , et al. Postoperative hormonal therapy after surgical excision of deep endometriosis. European Journal of Obstetrics and Gynecology and Reproductive Biology2017;209:77-80.">Somigliana 2017</a>). Furthermore, there is a lack of clarity regarding when the medical therapy should be used in relation to surgery (i.e. before, after, or both before and after the surgery), in order to maximize response to therapy. The evidence about combined use of surgery and medication needs critical review, with a special focus on timing of initiating use of medical therapy in relation to surgery. It is necessary to evaluate the benefits and consider the harms prior to recommending any specific combination strategy. This review aimed to evaluate the use of medical therapy before, after, or both before and after surgery for endometriosis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003678-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003678-sec-0014"></div> <p>To determine the effectiveness of medical therapies for hormonal suppression before, after, or both before and after surgery for endometriosis for improving painful symptoms, reducing disease recurrence, and increasing pregnancy rates. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003678-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003678-sec-0015"></div> <section id="CD003678-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003678-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomized controlled trials (RCT) where medical therapy for hormonal suppression of endometriosis was used before or after (or both) conservative surgery for endometriosis. We excluded quasi‐randomized trials. </p> </section> <section id="CD003678-sec-0018"> <h4 class="title">Types of participants</h4> <p> <ul id="CD003678-list-0001"> <li> <p>The study population included women of reproductive age (no age restriction included in this review) who underwent therapeutic surgery for endometriosis. We excluded studies that did not clarify whether a therapeutic procedure was performed or not during laparoscopy/laparotomy. </p> </li> <li> <p>All surgical procedures for the treatment of endometriosis that conserved the pelvic organs (such as ovarian cystectomy, drainage of endometriosis, excision, or ablation of endometriosis). We excluded women undergoing hysterectomy. </p> </li> <li> <p>The diagnosis of endometriosis could have been made provisionally by clinical examination or ultrasound (or both) and confirmed during the therapeutic surgery, or could have been surgically confirmed endometriosis from prior surgery. </p> </li> <li> <p>Women in at least one arm of trial would have medical therapy either before or after surgery. </p> </li> </ul> </p> </section> <section id="CD003678-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD003678-list-0002"> <li> <p>All systemic medical therapies for the hormonal suppression of endometriosis including GnRHas, danazol, progestogens, gestrinone, or the oral contraceptive pill (OCP) (or combinations of these) administered before or after (or both) surgery for endometriosis for the following comparisons: </p> <ul id="CD003678-list-0003"> <li> <p>presurgical medical therapy compared with placebo or no medical therapy;</p> </li> <li> <p>postsurgical medical therapy compared with placebo or no medical therapy;</p> </li> <li> <p>pre‐ and postsurgical medical therapy compared with placebo or no medical therapy;</p> </li> <li> <p>presurgical medical therapy compared with postsurgical medical therapy;</p> </li> <li> <p>postsurgical medical therapy compared with pre‐ and postsurgical medical therapy.</p> </li> </ul> </li> <li> <p>We used the term "surgery alone" to refer to placebo or no medical therapy.</p> </li> <li> <p>The use of medical therapy was considered at any dosage and for a period of at least three months before or after surgery. </p> </li> <li> <p>Only agents used with the aim of hormonal suppression were included (except for add‐back HTs to minimise adverse effects of primary hormonal agents). </p> </li> <li> <p>We excluded LNG‐IUD as it is non‐systemic.</p> </li> <li> <p>We excluded medical therapy with analgesics, anti‐inflammatory drugs, or antibiotics.</p> </li> <li> <p>We excluded alternative, dietary, or complementary therapeutic strategies.</p> </li> </ul> </p> </section> <section id="CD003678-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We compared the effectiveness of the use and timing of medical therapy as an adjunct to surgery for endometriosis to surgery alone (placebo or no medical therapy). </p> <section id="CD003678-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003678-list-0004"> <li> <p>Painful symptoms of endometriosis (including pelvic pain, dyspareunia, dysmenorrhea, pain recurrence) as measured by a visual analogue scale (VAS) of pain, other validated scales, or dichotomous outcomes. </p> </li> <li> <p>Recurrence of disease as evidenced by EEC (Endoscopic Endometriosis Classification), rAFS (revised American Fertility Society), or rASRM scores at second‐look laparoscopy. </p> </li> </ul> </p> </section> <section id="CD003678-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003678-list-0005"> <li> <p>Pregnancy rate per woman.</p> </li> <li> <p>Ease of surgery, duration of surgery, postsurgical complications.</p> </li> <li> <p>Levels of satisfaction of women.</p> </li> <li> <p>Adverse effects (proportion of women with one or more reported adverse effects associated with medical therapy). </p> </li> </ul> </p> </section> </section> </section> <section id="CD003678-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>Reports that described or might have described RCTs of hormonal suppression in the treatment of endometriosis before or after surgery were obtained from the following databases in consultation with Cochrane Gynaecology and Fertility (CGF) group information specialist. </p> <section id="CD003678-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic bibliographic databases, trial registers, and websites: </p> <p> <ul id="CD003678-list-0006"> <li> <p>The CGF Group Specialized Register of Controlled Trials; ProCite platform (searched 20 November 2019; <a href="./appendices#CD003678-sec-0109">Appendix 1</a>); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials; Ovid (CENTRAL; 2019, Issue 10) (<a href="./appendices#CD003678-sec-0110">Appendix 2</a>); </p> </li> <li> <p>MEDLINE – Epub ahead of print, In‐process &amp; Other non‐indexed citations; Ovid platform (searched from 1946 to 20 November 2019; <a href="./appendices#CD003678-sec-0111">Appendix 3</a>); </p> </li> <li> <p>Embase; Ovid platform (searched from 1980 to 20 November 2019; <a href="./appendices#CD003678-sec-0112">Appendix 4</a>); </p> </li> <li> <p>PsycINFO; Ovid platform (searched from 1806 to 20 November 2019; <a href="./appendices#CD003678-sec-0113">Appendix 5</a>); </p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature); Ebsco platform; (searched from 1961 to 20 November 2019; <a href="./appendices#CD003678-sec-0114">Appendix 6</a>). </p> </li> </ul> </p> <p>We combined the MEDLINE with the Cochrane highly sensitive search strategy for identifying RCTs, from Chapter 6 of the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD003678-bbs2-0050" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). We combined the Embase searches with trial filters developed by the Scottish Intercollegiate Guidelines Network (<a href="http://www.sign.ac.uk/what-we-do/methodology/search-filters/" target="_blank">www.sign.ac.uk/what-we-do/methodology/search-filters/</a>). </p> </section> <section id="CD003678-sec-0025"> <h4 class="title">Searching other resources</h4> <p>Other electronic sources of trials included the following.</p> <p> <ul id="CD003678-list-0007"> <li> <p>Trial registers for ongoing and registered trials: ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) and the World Health Organization International Trials Registry Platform search portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> <li> <p>PubMed and Google Scholar, for recent trials not yet indexed in the major databases.</p> </li> <li> <p>Reference lists and bibliographies of all relevant articles to identify additional trials for inclusion in this review. </p> </li> </ul> </p> <p>We sent letters to experts within the field, pharmaceutical companies producing the products being reviewed, and authors of unpublished abstracts to identify unpublished trials of medical therapy before or after surgery for endometriosis. </p> <p>We applied no language or date restrictions to the searches. We included a PRISMA flow chart to present the results of the search and the process of screening and selecting studies for inclusion in the review. </p> </section> </section> <section id="CD003678-sec-0026"> <h3 class="title" id="CD003678-sec-0026">Data collection and analysis</h3> <section id="CD003678-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AC and VV) independently selected trials for inclusion using <a href="./references#CD003678-bbs2-0038" title="Covidence. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>. We screened the titles and abstracts and discarded studies that were clearly ineligible, with an aim to be overly inclusive rather than risk losing relevant studies. We obtained full‐text articles. Both review authors independently assessed whether the studies met the inclusion criteria. We resolved disagreements by discussion between the review authors and lead author (IC). We sought further information from the authors where papers contained insufficient information to make a decision regarding eligibility. The selection process has been documented with a PRISMA flow chart (<a href="#CD003678-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD003678-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram." data-id="CD003678-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> </div> </section> <section id="CD003678-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Four review authors (AC, VV, AM and AZ) worked in pairs to extract data from eligible studies using a data extraction form designed and pilot‐tested by the authors. Two review authors extracted data for each study and resolved all disagreements by discussion. Data extracted included study characteristics and outcome data (see data extraction table for details in <a href="./appendices#CD003678-sec-0115">Appendix 7</a>). We corresponded with study authors for further information on methods and results, as required. </p> </section> <section id="CD003678-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Four review authors (AC, VV, AM and AZ) working in pairs assessed risk of bias using the Cochrane 'Risk of bias' tool (<a href="./references#CD003678-bbs2-0046" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). Seven domains for each included study evaluated random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, completeness of outcome data, risk of selective outcome reporting, and risk of other potential sources of bias (<a href="./appendices#CD003678-sec-0116">Appendix 8</a>). Two review authors assessed each study and assigned judgements as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 8.5; <a href="./references#CD003678-bbs2-0046" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We resolved disagreements by discussion among review authors and lead author (IC). All judgements are presented in the 'Risk of bias' table within the <a href="./references#CD003678-sec-0127" title="">Characteristics of included studies</a> table, which was later incorporated into the interpretation of review findings by means of sensitivity analysis. </p> <p>We sought additional information on trial methodology or original trial data from the principal authors of trials that appeared to meet the eligibility criteria but were unclear in aspects of methodology or outcomes, or where the data were in a form unsuitable for meta‐analysis. In the process, our team made attempt to contact twelve authors to obtain additional information about their study methods to clarify some of the aspects affecting assessment of risk of bias. </p> </section> <section id="CD003678-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data (e.g. pain recurrence), we used the numbers of events in the control and intervention groups of each study to calculate Mantel‐Haenszel risk ratios (RRs) with 95% confidence intervals (CI). For continuous data (e.g. pain by VAS), if all studies reported the same outcomes using the same scales, we calculated mean differences (MDs) between treatment groups and 95% CI. If studies had used different scale, we planned to use standardized mean differences (SMDs) with 95% CIs. </p> <p>We reversed the direction of effect of individual studies, if required, to ensure consistency across trials. We treated ordinal data (e.g. distribution of EEC stage) as dichotomous data. </p> <p>We assessed whether the estimates calculated in the review for individual studies were compatible in each case with the estimates reported in the study publications. </p> </section> <section id="CD003678-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis was per woman randomized to treatment. We did not include reported data that were based on a different unit of analysis (e.g. per endometrioma cyst) in the meta‐analyses, but summarized them in an additional table. </p> </section> <section id="CD003678-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We analyzed data on an intention‐to‐treat basis where possible, and attempted to contact authors to obtain missing data. Where studies reported data by type of medical therapy, we combined these treatment groups and compared them to placebo or no medical therapy using MD and the standard deviation for continuous outcomes. Where the mean and standard deviation for the combined groups was not reported. we estimated it using the formulae described in Table 7.7a in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003678-bbs2-0046" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD003678-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity using the I<sup>2</sup> statistic. An I<sup>2</sup> statistic greater than 50% indicated substantial heterogeneity (<a href="./references#CD003678-bbs2-0046" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD003678-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. </p> </section> <section id="CD003678-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analysis in accordance with the guidelines for statistical analysis developed by the Cochrane using Review Manager 5 (<a href="./references#CD003678-bbs2-0055" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>If the studies were sufficiently similar, we used a fixed‐effect analysis. Where possible, we pooled the outcomes statistically. For dichotomous data (e.g. proportion of women with pain recurrence at 12 months), we expressed results for each study as RR with 95% CI and combined for meta‐analysis with Review Manager 5 software using the Mantel‐Haenszel method (<a href="./references#CD003678-bbs2-0055" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>For continuous outcomes (e.g. multidimensional pain scores), we combined means and standard deviations for each group in the meta‐analysis as MD or SMD and 95% CIs. </p> <p>Comparison was organized for following study hypotheses:</p> <p> <ul id="CD003678-list-0008"> <li> <p>presurgical medical therapy compared with placebo or no medical therapy;</p> </li> <li> <p>postsurgical medical therapy compared with placebo or no medical therapy;</p> </li> <li> <p>pre‐ and postsurgical medical therapy compared with placebo or no medical therapy;</p> </li> <li> <p>presurgical medical therapy compared with postsurgical medical therapy;</p> </li> <li> <p>postsurgical medical therapy compared with pre and postsurgical medical therapy.</p> </li> </ul> </p> <p>Within each hypothesis, comparison were ordered for pain (VAS, 36‐item Short Form (SF‐36) pain score, pain recurrence, disease recurrence (continuous, dichotomous, EEC stage), and pregnancy rate (where data were available). </p> </section> <section id="CD003678-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>A priori, it was planned to look at the possible contribution of differences in trial design, medical therapy used, timing of therapy, dosage, mode of administration, and duration of therapy to any heterogeneity identified. </p> </section> <section id="CD003678-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses where there were sufficient trials included, in order to determine whether the conclusions were robust (i.e. whether conclusions would have differed if the inclusion of trials was restricted to those with low risk of bias). We performed this sensitivity analysis for the primary outcomes only. We also performed a sensitivity analysis comparing outcomes based on random‐effects model. </p> <section id="CD003678-sec-0038"> <h5 class="title">Overall quality of the body of evidence: 'Summary of findings' tables</h5> <p>We prepared 'Summary of findings' tables using GRADEpro and Cochrane methods (<a href="./references#CD003678-bbs2-0043" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD003678-bbs2-0046" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). These tables evaluated the overall quality of the body of evidence for the main review outcomes for the main review comparisons. The main review outcomes were Pelvic pain at 12 months or less (continuous), Pain recurrence at 12 months or less (dichotomous), disease recurrence at 3 months ‐ Total (AFS score ‐ continuous), disease recurrence at 12 months or less (dichotomous), disease recurrence at 12 months or less (EEC stage‐ dichotomous), and pregnancy rate (dichotomous). The main review comparisons were: </p> <p> <ul id="CD003678-list-0009"> <li> <p>presurgical medical therapy compared with placebo or no medical therapy;</p> </li> <li> <p>postsurgical medical therapy compared with placebo or no medical therapy;</p> </li> <li> <p>pre‐ and postsurgical medical therapy compared with placebo or no medical therapy;</p> </li> <li> <p>presurgical medical therapy compared with postsurgical medical therapy;</p> </li> <li> <p>postsurgical medical therapy compared with pre‐ and postsurgical medical therapy.</p> </li> </ul> </p> <p>We assessed the quality of the evidence using GRADE working group criteria: risk of bias, consistency of effect, imprecision, indirectness, and publication bias. Two review authors independently made judgements about evidence quality (high, moderate, low, or very low), with disagreements resolved by discussion. Judgements were justified, documented, and incorporated into reporting of results for each outcome. We first extracted study data, formatted our comparisons in data tables, and prepared 'Summary of findings' tables before writing the results and conclusions of our review. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003678-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003678-sec-0039"></div> <section id="CD003678-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD003678-sec-0041"> <h4 class="title">Results of the search</h4> <p>The search retrieved 1084 articles, which included 16 articles included in previous version of the review (<a href="./references#CD003678-bbs2-0061" title="FurnessS , YapC , FarquharC , CheongYC . Pre and post-operative medical therapy for endometriosis surgery. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003678. [DOI: 10.1002/14651858.CD003678.pub2]">Furness 2004</a>). We excluded one of the previously included articles because of the improper randomization procedure used in allocation of intervention (<a href="./references#CD003678-bbs2-0026" title="BatiogluS , HaberaiA , CelikkanatH . Comparison of GnRH agonist administration before and after laparoscopic drainage of endometriomas. Journal of Gynecologic Surgery1997;13(1):17-21. ">Batioglu 1997</a>). Among the remaining newly retrieved 1068 articles, after removing the duplicates, 852 were left for analysis. A total of 265 articles were potentially eligible and were retrieved in full text. Upon closer examination, 238 articles did not meet the inclusion criteria due to ineligible study design, ineligible intervention, ineligible comparator, ineligible outcome, ineligible study population, or duplicate publication (<a href="#CD003678-fig-0001">Figure 1</a>). Twenty‐five studies finally met our inclusion criteria, for both systematic review and meta‐analysis, including 3378 women (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). Fifteen were already included in the previous version of this review (<a href="./references#CD003678-bbs2-0061" title="FurnessS , YapC , FarquharC , CheongYC . Pre and post-operative medical therapy for endometriosis surgery. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003678. [DOI: 10.1002/14651858.CD003678.pub2]">Furness 2004</a>). See <a href="./references#CD003678-sec-0127" title="">Characteristics of included studies</a> and <a href="./references#CD003678-sec-0128" title="">Characteristics of excluded studies</a> tables. We attempted to contact four authors to obtain additional information about the data presented in published paper; however only one responded with minimal additional information, which we included in the review. One study is awaiting classification (<a href="./references#CD003678-bbs2-0032" title="RoghaeiMA , TehranyHG , TaherianA , KoleiniN . Effects of letrozole compared with danazol on patients with confirmed endometriosis: a randomized clinical trial. International Journal of Fertility and Sterility2010;4:67-72. ">Roghaei 2010</a>). We identified no ongoing studies. </p> </section> <section id="CD003678-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD003678-sec-0043"> <h5 class="title">Study design and settings</h5> <p>We included 25 RCTs.</p> <p>The original search identified 11 trials that met the inclusion criteria (<a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>; <a href="./references#CD003678-bbs2-0026" title="BatiogluS , HaberaiA , CelikkanatH . Comparison of GnRH agonist administration before and after laparoscopic drainage of endometriomas. Journal of Gynecologic Surgery1997;13(1):17-21. ">Batioglu 1997</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>). The first updated search (in September 2010) identified a further six trials which met the inclusion criteria (<a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>; <a href="./references#CD003678-bbs2-0029" title="ShawkiO , HamzaH , SattarM . Mild endometriosis, to treat or not treat: randomized controlled trial comparing diagnostic laparoscopy with no further treatment versus post operative Zoladex in cases with infertility associated with stage I, II endometriosis. Fertility and Sterility2002;77 Suppl 1:13. ">Shawki 2002</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>). One trial was published only as an abstract, with insufficient information available to include it in this review (<a href="./references#CD003678-bbs2-0029" title="ShawkiO , HamzaH , SattarM . Mild endometriosis, to treat or not treat: randomized controlled trial comparing diagnostic laparoscopy with no further treatment versus post operative Zoladex in cases with infertility associated with stage I, II endometriosis. Fertility and Sterility2002;77 Suppl 1:13. ">Shawki 2002</a>). We attempted to contact the author to obtain additional information without success. This study was then listed under studies awaiting classification, in previous versions and has now been excluded from this review. One study was included in the previous review, but excluded in this updated version of the review, due to quasi‐randomization of this study (using odd and even numbers) (<a href="./references#CD003678-bbs2-0026" title="BatiogluS , HaberaiA , CelikkanatH . Comparison of GnRH agonist administration before and after laparoscopic drainage of endometriomas. Journal of Gynecologic Surgery1997;13(1):17-21. ">Batioglu 1997</a>). This updated review identified 10 trials that met the inclusion criteria (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). <a href="./references#CD003678-bbs2-0029" title="ShawkiO , HamzaH , SattarM . Mild endometriosis, to treat or not treat: randomized controlled trial comparing diagnostic laparoscopy with no further treatment versus post operative Zoladex in cases with infertility associated with stage I, II endometriosis. Fertility and Sterility2002;77 Suppl 1:13. ">Shawki 2002</a> was still not published, and, therefore, excluded from the recent updated review. </p> <p>Of the 25 trials now included in this review, 13 were conducted in Italy (<a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>); three in China (<a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>); two in Germany (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>); and one each in Belgium (<a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>), Finland (<a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>), France (<a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>), Taiwan (<a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>), Thailand (<a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>), UK/Republic of Ireland (<a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>), and USA (<a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>). </p> <p>Five reports declared pharmaceutical support for their studies (<a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>), while two had independent funding respectively from Fonds de la Recherche Scientifique (<a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>) and Research and Science Foundation Farmos Ltd, Turku (<a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>). <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a> received funding from the Natural Science Foundation of Heilongjiang Province. The remainder did not describe any form of funding or support. </p> </section> <section id="CD003678-sec-0044"> <h5 class="title">Participants</h5> <p>The trials included 3378 women who underwent conservative therapeutic surgery for endometriosis, and were randomly allocated to pre‐ or postsurgical (or both) medical therapy or placebo or surgery alone, depending on the study's protocol. The ages of included women ranged from 18 to 50 years. </p> </section> <section id="CD003678-sec-0045"> <h5 class="title">Interventions</h5> <p>Medical therapy included GnRHas (goserelin, leuprorelin, nafarelin, triptorelin), danazol, letrozole, progestogen (gestrinone, medroxyprogesterone acetate), and the combined OCP. Of the 25 studies included in this review, six mentioned the effects of the combined OCP (<a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>), two of which also mentioned the effect of triptorelin (<a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>). Other participants were randomly allocated to medical therapy which included GnRHas (goserelin, leuprorelin, nafarelin, triptorelin) (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>), danazol (<a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>), or progestogen (gestrinone, desogestrel, medroxyprogesterone acetate) (<a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>). </p> <section id="CD003678-sec-0046"> <h6 class="title">Presurgical medical therapy compared with placebo or no medical therapy</h6> <p>Three trials compared presurgical medical therapy for endometriosis to surgery alone (no medical therapy) (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>). </p> <p><a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> compared three groups, with different timing of medical or surgical treatment. The study comprised 450 participants, aged 18 to 44 years, with symptomatic endometriosis. The authors compared two consecutive laparoscopic surgeries. Each group consisted of 150 participants, randomly allocated. For the analysis of presurgical medical therapy compared to surgery alone, we used only two groups in this review, namely medical therapy with subcutaneous leuprorelin acetate depot injected monthly for three months before surgery (group 1) and surgical treatment without hormonal postsurgical therapy (group 2). The authors performed a second‐look laparoscopy one to two months after conclusion of the HT in group 1 and five months after the first laparoscopy in group 2. They staged endometriosis according to the EEC, and obtained data regarding pregnancy rate and recurrence of pain symptoms. </p> <p><a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a> included 80 women with infertility who were aged less than 35 years with laparoscopically confirmed ovarian endometriotic cysts, which were drained and flushed out laparoscopically. They randomized participants to receive a subcutaneous goserelin implant four‐weekly for 12 weeks or no treatment. Twelve weeks after the first‐look laparoscopy, they performed another laparoscopy during which a biopsy was done, and endometriosis and cyst wall vaporized. The same two observers used AFS scoring. </p> <p><a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a> randomized 48 women aged 18 to 50 years who had been referred for management of symptoms or infertility due to endometrioma. After the cysts were aspirated, women received either goserelin four‐weekly for three months or no medical therapy. Following an ultrasound measurement of the residual cysts, women underwent definitive excision and were then followed for a further six months. Outcomes included size of endometrioma presurgery, proportion of participants who had complete excision of cysts, AFS scores, and recurrence of cysts measured by ultrasound at six months. </p> </section> <section id="CD003678-sec-0047"> <h6 class="title">Postsurgical medical therapy compared with placebo or no medical therapy</h6> <p>Twenty‐two studies assessed postsurgical medical therapy for endometriosis. Seven compared postsurgical medical therapy to placebo (<a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>). Different forms of hormonal medication were compared to placebo, namely GnRHas, danazol, letrozole, OCP, and progestogen. The remaining 15 trials received the control group surgery alone with no medical therapy (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). </p> <p>Two studies compared intranasal nafarelin (400 μg/day) with placebo over six months (<a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>) and three months (<a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>). <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a> randomly allocated 49 to nafarelin and 44 to placebo; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a> randomly allocated 36 to nafarelin and 39 to placebo. three studies randomized women for postsurgical triptorelin depot or placebo (<a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>). </p> <p><a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a> analyzed 62 women and <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a> analysed 54 women with symptomatic endometriosis and compared triptorelin depot to placebo, evaluating pain recurrence, endometrioma relapse, and pregnancy rate. <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a> randomly allocated 234 women and <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a> randomly allocated 259 women with endometriosis to postsurgical medical therapy with GnRHas (either triptorelin or leuprorelin), continuous estroprogestin (OCP), dietary therapy (vitamins, minerals, lactic ferments, and fish oil), or placebo and evaluated pain (dysmenorrhoea, non‐menstrual pelvic pain, and dyspareunia) and quality of life. We combined data from the two hormonal suppression arms and compared them to placebo in the meta‐analysis. Data from the dietary therapy were not used in the meta‐analysis. </p> <p><a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a> compared danazol therapy with placebo. <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a> had three groups, medroxyprogesterone acetate (MPA) 100 mg/day taken orally for six months (n = 17) and danazol 600 mg/day (200 mg three time daily) for six months (n = 18), compared to placebo (n = 16). Outcome measurements included pain recurrence, pregnancy rate, and disease recurrence determined by second‐look laparoscopy. <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a> reported data separately for each group (see <a href="#CD003678-tbl-0004">Table 1</a>). In the meta‐analysis, we combined data from the medical therapy groups. The last placebo‐controlled trial of postsurgical medical therapy compared 20 women receiving desogestrel 0.075 mg with 20 women receiving placebo (<a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>). The outcome measurement was pain recurrence, subdivided as overall pain, dysmenorrhoea, and noncyclic pelvic pain. </p> <div class="table" id="CD003678-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Descriptive data for trials not included in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Conclusion</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical vs no treatment, 2 groups (A = complete excision, B = incomplete excision, 1 = no therapy, 2 = GnRHas). 1A vs 2A </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Differences in participant's quality of life by SF‐36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P &lt; 0.001) for general health, physical function, and vitality after 12 months of complete excision vs complete excision + GnRHas. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical vs no therapy, 2 groups (A = complete excision, B = incomplete excision, 1 = no therapy, 2 = GnRHas). 1A 12 months' follow‐up vs baseline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P &lt; 0.001) for general health, physical function, and vitality 12 months' follow‐up vs baseline for complete excision. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical vs no therapy, 2 groups (A = complete excision, B = incomplete excision, 1 = no therapy, 2 = GnRHas). 2A 12 months' follow‐up vs baseline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P &lt; 0.001) for general health, physical function, and vitality 12 months' follow‐up vs baseline for complete excision + GnRHas. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Presurgical vs postsurgical GnRHa (nafarelin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AFS scores – total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total AFS score after 6 months was 0 in presurgery group and 6 in postsurgery group (P = 0.007); no SD or SE given and not calculable. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AFS scores – adhesion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adhesion AFS score after 6 months was 0 in presurgery group and 2 in postsurgery group (P = 0.007), no SD or SE given and not calculable. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AFS scores – implant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Implant AFS score after 6 months was 0 in presurgery group and 4 in postsurgery group (P = 0.05), no SD or SE given and not calculable. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ease of surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery was easy in 56% of participants with GnRHa therapy presurgery compared to 35.7% in the postsurgery group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presurgical GnRHa (goserelin) vs no medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean endometrioma size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favouring goserelin: mean difference –1.81 cm (95% confidence interval –2.05 to 1.57).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical vs no therapy, GnRHas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total effective rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant higher total effective rate compared to control group in favour of GnRHas group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical vs no medical therapy (cyclic and continuous OC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative pain‐free interval</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87/187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant higher in continuous users vs cyclic (P &lt; 0.0005) and in cyclic vs non‐users (P = 0.01) 18 months postsurgical. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Presurgical GnRHa (goserelin) vs no medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in endometrioma size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favouring goserelin: adjusted mean difference –1.25 cm (95% confidence interval –2.42 to –0.08). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete excision of cyst</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference. 13/21 (72%) in GnRHa group and 16/27 (73%) in no medical therapy group had cysts completely excised at surgery. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of residual cysts at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favours goserelin. 2/21 (10%) in GnRHa and 4/27 (15%) in no medical treatment had recurrence of residual cysts. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean rAFS scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference. 41.7 in GnRHa group and 42.5 in no medical treatment group (no SD given).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MPA vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain scores after 12 months assessed with 4‐point scales; 1.8 in MPA group and 4.4 in placebo group; "significant difference." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danazol vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain scores after 12 months assessed with 4‐point scales; 2.5 in danazol group and 4.4 in placebo group; "significant difference." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MPA vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant satisfaction achieved in 84% in MPA group and 24% in placebo group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danazol vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant satisfaction achieved in 84% in danazol group and 24% in placebo group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical leuprolide/danazol vs no therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative pregnancy rate at 12 months after clomiphene stimulation in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference; 56.7% in leuprolide/danazol group and 54.5% in no therapy group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical gestrinone vs no medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease recurrence at 6–30 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favoured medical therapy; 1/19 in gestrinone group and 4/13 in no medical therapy group (P &lt; 0.05). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Postsurgical triptorelin acetate vs no medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total effective rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant higher total effective rate in triptorelin group vs control group (P = 0.009). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levels of E<sub>2</sub>, LH, and FSH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levels were significantly lower in the triptorelin acetate group than in control group (P &lt; 0.001). </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AFS: American Fertility Society; FSH: follicle‐stimulating hormone; GnRHa: gonadotropin‐releasing hormone agonist; LH: luteinizing hormone; MPA: medroxyprogesterone acetate; n: number of participants; SD: standard deviation; SE: standard error; SF‐36: 36‐item Short Form. </p> </div> </div> <p>Fifteen trials compared postsurgical medical therapy with GnRHas, danazol, progestogen, or OCPs with no postsurgical medical therapy (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a> compared postsurgical danazol 600 mg/day for three months with surgery alone in 53 women. Ten studies compared postsurgical GnRHas administered subcutaneously every four weeks with surgery alone (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). <a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> compared medical therapy with subcutaneous leuprorelin acetate 3.75 mg depot injected monthly for three months after surgery (group 3) compared with no hormonal therapy after surgery (group 2). In both groups, 150 participants were randomized. <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a> randomized 44 participants to receive leuprolide acetate depot 3.75 mg every four weeks for eight weeks (three injections) compared to 45 participants without postsurgical therapy. Outcome measurements were pain recurrence, disease recurrence, and pregnancy rate at 18 months. <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a> randomly allocated 15 women to postsurgical therapy with either GnRHas (leuprolide, n = 8) or danazol (n = 7), and the remaining 30 to no postsurgical medical therapy prior to controlled ovarian hyperstimulation with clomiphene followed by intrauterine insemination (IUI) or IVF. </p> <p>Two studies compared triptorelin acetate depot 3.75 mg with no postsurgical therapy in 79 women (<a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>) and 65 women (<a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). Both treated women with endometriosis for six months with triptorelin acetate depot. <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a> compared GnRHas with no medical therapy after surgery for four to six months, but there is no mention of which GnRHas was used. <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a> and <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a> both compared goserelin with no hormonal therapy. <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a> enrolled 110 women with stage II to IV endometriosis and randomized them to two groups, 55 women received goserelin after surgery, and 55 women received surgery alone. After randomizations and therapy with GnRHas or no medical therapy, women were divided in two groups for ART, namely IUI or IVF/intracytoplasmic sperm injection (ICSI). <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a> compared 133 women in the goserelin group versus 134 in the control group for six months after surgery. <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a> compared postsurgical triptorelin, administered subcutaneously every four weeks for 12 weeks, with surgery alone in groups of 62 women with endometriosis. In China, <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a> compared postsurgical therapy with traditional Chinese medicine, gestrinone, or no therapy in 52 women and reported the pregnancy rate and recurrence of endometriosis with a nine‐ and 30‐month follow‐up. </p> <p>Four studies investigated the effectiveness of OCPs (<a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>). <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a> randomized 130 women into three groups with two monophasic and one multiphasic OCP. Non‐users did not received HT after surgery and were the control group. <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a> compared surgery plus six months of therapy with low‐dose cyclical OCP to surgery alone. <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a> and <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a> compared cyclic and continuous OCP use to non‐users. Group A (non‐users) included 69 (<a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>) and 87 (<a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>) women. Group B (cyclic OC users) included after randomizations 75 (<a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>) and 92 (<a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>) women, compared to group C (continuous OC users) with 73 (<a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>) and 95 (<a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>) women. Therapy with OCP was continued for at least 24 months. </p> </section> <section id="CD003678-sec-0048"> <h6 class="title">Pre‐ and postsurgical medical therapy compared with surgery alone or surgery and placebo</h6> <p>We found no studies comparing pre‐ and postsurgical medical therapy with surgery alone or surgery and placebo. </p> </section> <section id="CD003678-sec-0049"> <h6 class="title">Presurgical medical therapy compared with postsurgical medical therapy</h6> <p>Two studies compared presurgical medical therapy with postsurgical medical therapy (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>). <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a> compared medical therapy with intranasal nafarelin administered daily for six months before surgery with intranasal nafarelin administered daily for six months after surgery. Outcomes were pain, AFS scores, and ease of surgery. <a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> compared three groups, with different timings of medical or surgical treatment. For the analysis of presurgical medical therapy compared to postsurgical medical therapy, we used only two groups, namely medical therapy with subcutaneous leuprorelin acetate depot injected monthly for three months before surgery (group 1) compared to postsurgical hormonal therapy with the same medication as group 1 (group 3). The study performed a second‐look laparoscopy at one to two months after conclusion of therapy. Authors staged endometriosis according to the EEC, and reported data for pregnancy rate and recurrence of pain symptoms. </p> </section> <section id="CD003678-sec-0050"> <h6 class="title">Postsurgical medical therapy compared with pre‐ and postsurgical medical therapy</h6> <p>We found no studies comparing postsurgical medical therapy with pre‐ and postsurgical medical therapy. </p> </section> </section> <section id="CD003678-sec-0051"> <h5 class="title">Outcomes</h5> <p>Twenty‐two studies reported one or more of our primary outcomes (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). The other three studies only mentioned secondary outcomes (<a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>). </p> </section> </section> <section id="CD003678-sec-0052"> <h4 class="title">Excluded studies</h4> <p>We excluded 238 studies from the review due to their non‐conformity with review objectives and methods for following reasons: </p> <p> <ul id="CD003678-list-0010"> <li> <p>66 had ineligible study population;</p> </li> <li> <p>40 had ineligible intervention;</p> </li> <li> <p>75 had ineligible comparator;</p> </li> <li> <p>21 had ineligible outcome;</p> </li> <li> <p>35 had ineligible study design;</p> </li> <li> <p>one was a duplicate publication of another study already included in review (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>). </p> </li> </ul> </p> <p>Five key excluded studies are listed below and are described in further detail in the <a href="./references#CD003678-sec-0128" title="">Characteristics of excluded studies</a> table. </p> <p> <ul id="CD003678-list-0011"> <li> <p><a href="./references#CD003678-bbs2-0027" title="MorganteG , DittoA , MarcaAL , LeoVD . Low-dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis. Human Reproduction1999;14(9):2371-4. ">Morgante 1999</a>: all participants received triptorelin for six months postsurgery before randomization to danazol or no therapy. </p> </li> <li> <p><a href="./references#CD003678-bbs2-0028" title="SchindlerAE , BuhlerK , LubbenG , KienleE . Managment of endometriosis through a combined medical-surgical approach [Was leistet die kombinierte chirurgisch-hormonell Therapie zum Management der Endometriose]. Zentralblatt fur Gynakologie1998;120:183-90. ">Schindler 1998</a>: a prospective multicentre phase three study published in German. Preliminary translation suggested treatment was not randomly assigned. </p> </li> <li> <p><a href="./references#CD003678-bbs2-0029" title="ShawkiO , HamzaH , SattarM . Mild endometriosis, to treat or not treat: randomized controlled trial comparing diagnostic laparoscopy with no further treatment versus post operative Zoladex in cases with infertility associated with stage I, II endometriosis. Fertility and Sterility2002;77 Suppl 1:13. ">Shawki 2002</a>: data were not available at the time of writing this review. </p> </li> <li> <p><a href="./references#CD003678-bbs2-0030" title="VercelliniP , FrontinoG , GiorgiOD , AimiG , ZainaB , CrosignaniPG . Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertility and Sterility2003;80(2):305-9. ">Vercellini 2003</a>: a pilot study using the LNG‐IUS for treatment of endometriosis postsurgery. This is a locally effective hormonal suppressive therapy and has low systemic effects. </p> </li> <li> <p><a href="./references#CD003678-bbs2-0031" title="YlanenK , LaatikainenT , LahteenmakiP , Moo-YoungAJ . Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses. Acta Obstetricia et Gynecologica Scandinavica2003;82:167-72. ">Ylanen 2003</a>: a dose finding study with no comparison of treatment modality with placebo or no medical therapy. </p> </li> </ul> </p> <p>In addition, we excluded one previously included trial (<a href="./references#CD003678-bbs2-0026" title="BatiogluS , HaberaiA , CelikkanatH . Comparison of GnRH agonist administration before and after laparoscopic drainage of endometriomas. Journal of Gynecologic Surgery1997;13(1):17-21. ">Batioglu 1997</a>), which was a quasi‐RCT, where randomization took place by even and odd numbers. </p> </section> </section> <section id="CD003678-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>Refer to the 'Risk of bias' tables and <a href="#CD003678-fig-0002">Figure 2</a> and <a href="#CD003678-fig-0003">Figure 3</a>. Of the 25 trials included in this review, only four could be considered at low risk of bias overall (<a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>) (see <a href="#CD003678-fig-0003">Figure 3</a>). We attempted to contact 12 authors to obtain additional information about their study methods to clarify some of the aspects affecting assessment of risk of bias; however, only two authors responded and the risk of bias assessment for their studies was updated accordingly. </p> <div class="figure" id="CD003678-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003678-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003678-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003678-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003678-sec-0054"> <h4 class="title">Allocation</h4> <section id="CD003678-sec-0055"> <h5 class="title">Sequence generation</h5> <p>Sixteen studies used computer‐generated randomization (<a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>) and two used randomization tables (<a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>). These studies were at low risk of bias for this domain. The remainder of studies did not state their method of randomization and were, therefore, at unclear risk for this domain (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). </p> </section> <section id="CD003678-sec-0056"> <h5 class="title">Allocation concealment</h5> <p>Two studies reported adequate allocation concealment using telephone allocation (<a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>). Six studies allocated participants using serially numbered opaque, sealed envelopes (<a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>), while <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a> allocated participants according to list "unknown to physicians." These nine studies were at low risk of bias. The remainder of the included studies did not describe their allocation methods and were at unclear risk of bias. </p> </section> </section> <section id="CD003678-sec-0057"> <h4 class="title">Blinding</h4> <section id="CD003678-sec-0058"> <h5 class="title">Performance bias</h5> <p>Eight studies were double blinded and at low risk of performance bias (<a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>;<a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>). <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a> blinded participants to treatment allocation and used placebo injections, so were at low risk of performance bias. </p> <p>One study was open label and at high risk of bias for performance bias (<a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>). There was insufficient information to assign the remaining studies, so they were at unclear risk of performance bias. </p> </section> <section id="CD003678-sec-0059"> <h5 class="title">Detection bias</h5> <p>Eight studies were double blinded and at low risk of detection bias (<a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>). For detection bias, if objective outcome measures were used, such as pregnancy rate and recurrence of endometriosis, detection bias was considered unlikely and assessed at low risk of bias. In case of subjective outcome measure used (pain), there was a high risk of bias. If both objective and subjective outcomes were included, there was an unclear risk of bias. </p> <p>Seven studies used objective outcome measures, such as pregnancy rate and recurrence of endometriosis (<a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). As a result, detection was unlikely, and detection bias was low risk. Three studies were at high risk of bias, due to use of a subjective outcome measure (pain) (<a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>). One study was open label and at high risk of detection bias (<a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>). If both objective and subjective outcome measures were represented in the study, where there was no blinding, detection bias was assigned as unclear risk. <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a> was at unclear risk of bias because there was no information available to determine detection bias. There was insufficient information to assign the remaining studies, so they were at unclear risk of detection bias. </p> <p>In all the studies included in this review, the adverse effects of the medication may have alerted the investigators and participants to the type of medical intervention. </p> </section> </section> <section id="CD003678-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>Sixteen studies were at low risk of bias for this domain, six had no postrandomization losses (<a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>), and 10 trials had few postrandomization losses (<a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>: 11% evenly divided, <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>: 3%; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>: 15% evenly divided, <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>: 4%; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>: 9.1%, <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>: 9.2%; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>: 5.1%; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>: 7.3%; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>: 5%; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>: 2%). </p> <p>Outcome data was incomplete in six studies and at high risk of attrition bias (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>). <a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> had a lost to follow‐up of 40/450 participants, which were unevenly divided between groups. <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a> noted a lost to follow‐up of 8/38 (21%) participants in the non‐users group compared to 29/130 in the three treated groups combined. <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a> had a lost to follow‐up of 1/30 participants in the triptorelin group compared to 5/30 participants in the placebo group. <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a> had a lost to follow‐up of 37/239 participants, most of them in the non‐users group. <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a> noted a lost to follow‐up in the goserelin group of 7/21 (33%) participants and no therapy group of 11/27 (41%) participants. <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a> had a lost to follow‐up of four participants, all in the non‐users group (4/15). A further three studies were at unclear risk of bias for this domain (<a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>). </p> <p>Eleven studies reported pregnancy rates (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). </p> <p><a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a> and <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a> reported pregnancy rates 12 months after treatment commenced as an outcome for all participants in the trials; losses to follow‐up were small (<a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>: 9%; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>: 2%). <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a> had also a follow‐up rate for pregnancy of 12 months, but the lost to follow‐up was not mentioned clearly. <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a> and <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a> reported pregnancy rates after 18 months' follow‐up in a subgroup of participants (<a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>: 30%; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>: 40% of participants). <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a> reported no losses to follow‐up in the group desiring pregnancy and <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a> did not state whether there were any losses to follow‐up. <a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> and <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a> reported 12 months' follow‐up. <a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> compared three groups, namely HT (n = 125), surgery alone (n = 137), and HT plus surgery (n = 148). Pregnancy rate was assessed in 125 women in the HT group, 137 in the surgery alone group and 148 in HT plus surgery grooup. <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a> reported pregnancy outcomes in a subgroup of 152 women desiring fertility (56% of participants) after two years of follow‐up; losses to follow‐up in these groups were very small. <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a> had a follow‐up period of five years, with an unclear lost to follow‐up risk of bias. <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a> reported the results of assisted reproduction, in five or six cycles of medication or five to six months without medication. The follow‐up from <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a> was six to 30 months after treatment, with almost no lost to follow‐up. </p> </section> <section id="CD003678-sec-0061"> <h4 class="title">Selective reporting</h4> <p>Twenty‐one studies reported our main review outcomes. Twenty were at low risk of selective reporting (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). We rated one study at unclear risk of selective reporting, as it reported insufficient data for review authors to make a judgement (<a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>). </p> </section> <section id="CD003678-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>Eight studies were at unclear risk of other bias. One trial, which was described as an RCT, reported that participants were "randomly selected to receive" postsurgical medical therapy prior to ovarian stimulation over 13 years (1988 to 2001) (<a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>). This might have given bias on pregnancy rate data. During this time there have been significant advancements in endoscopic technology. It is unclear whether this resulted in any bias in the results of the study. In addition, there were statistical differences between time from surgery to start of ovarian stimulation and number of oocytes and embryos per cycle in this study (<a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>). One study reported differences between the groups at baseline with regard to disease severity, which may have introduced a bias into the results from this study (<a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>). <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a> reported differences between the four groups, the rate of participants reporting dysmenorrhoea in the GnRHas group was significant lower compared to the other groups. <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>, <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>, <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>, and <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a> did not report the characteristics of each group at baseline. </p> </section> </section> <section id="CD003678-sec-0063"> <h3 class="title" id="CD003678-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD003678-tbl-0001"><b>Summary of findings 1</b> Presurgical medical therapy compared with placebo or no medical therapy</a>; <a href="./full#CD003678-tbl-0002"><b>Summary of findings 2</b> Postsurgical medical therapy compared with placebo or no medical therapy</a>; <a href="./full#CD003678-tbl-0003"><b>Summary of findings 3</b> Presurgical medical therapy compared with postsurgical medical therapy</a> </p> <section id="CD003678-sec-0064"> <h4 class="title">1. Presurgical medical therapy compared with placebo or no medical therapy</h4> <p>(Analysis 1.1; Analysis 1.2; Analysis 1.3; Analysis 1.4; <a href="#CD003678-tbl-0004">Table 1</a>) </p> <p>Three studies compared presurgical medical therapy with placebo or no medical therapy (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>). There were too few studies to conduct any planned sensitivity analyses. </p> <section id="CD003678-sec-0065"> <h5 class="title">1.1 Pain (continuous)</h5> <p>No studies reported pain.</p> </section> <section id="CD003678-sec-0066"> <h5 class="title">1.2 Pain recurrence (dichotomous)</h5> <p>One trial included pain as dichotomous outcome measure (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>). </p> <p>We are uncertain if there is a difference in pelvic pain recurrence at 12 months or less (dichotomous) between presurgical medical hormonal suppression and surgery alone (RR 1.10, 95% CI 0.72 to 1.66; 1 RCT, n = 262; very low‐quality evidence). The evidence suggests that if the pelvic pain recurrence at 12 months or less (dichotomous) is assumed to be 24% among women with surgery alone, the chance following presurgical medical hormonal suppression would be between 17% and 40% (Analysis 1.1). </p> <p>We are uncertain if there is a difference in dysmenorrhoea recurrence at 12 months or less (dichotomous) between presurgical medical hormonal suppression and surgery alone (RR 1.42, 95% CI 0.92 to 2.21; 1 RCT, n = 262; very low‐quality evidence; Analysis 1.1). </p> <p>We are uncertain if there is a difference in dyspareunia recurrence at 12 months or less (dichotomous) between presurgical medical hormonal suppression and surgery alone (RR 1.46, 95% CI 0.88 to 2.44; 1 RCT, n = 262; very low‐quality evidence; Analysis 1.1). </p> </section> <section id="CD003678-sec-0067"> <h5 class="title">1.3 Disease recurrence (continuous)</h5> <p>Two trials used AFS scores as the outcome measure in comparing medical therapy presurgery with surgery alone (<a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a>; <a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a>). There was insufficient evidence to determine whether there was a difference in endometrioma cyst size (<a href="#CD003678-tbl-0004">Table 1</a>), total AFS scores, and implant AFS scores comparing presurgical goserelin treatment with no treatment (Analysis 1.2). </p> <p>We are uncertain about the improvement in disease recurrence at three months – total (AFS score) between presurgical medical hormonal suppression and surgery alone (mean recurrence score was 9.6 lower, 95% CI 11.42 to 7.78 lower; 1 RCT, n = 80; very low‐quality evidence; Analysis 1.2). </p> <p>We are uncertain about the improvement in disease recurrence at three months – implant (AFS score) between presurgical medical hormonal suppression and surgery alone (mean recurrence score was 8.70 lower, 95% CI 10.67 to 6.73 lower; 1 RCT, n = 80; very low‐quality evidence; Analysis 1.2). </p> <p>We are uncertain if there is a difference in disease recurrence at three months – adhesions (AFS score) between presurgical medical hormonal suppression and surgery alone (mean recurrence score was 0.90 lower, 95% CI 3.42 lower to 1.62 higher; 1 RCT, n = 80; very low‐quality evidence; Analysis 1.2). </p> </section> <section id="CD003678-sec-0068"> <h5 class="title">1.4 Disease recurrence (dichotomous)</h5> <p>The distribution of EEC stage, mentioned in <a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>, showed insufficient evidence to determine a difference after presurgical therapy with leuprorelin compared to no presurgical therapy (Analysis 1.3). </p> <p>We are uncertain if there is a difference observed in disease recurrence at 12 months or less (EEC stage) between presurgical medical hormonal suppression and surgery alone (RR 1.11, 95% CI 0.86 to 1.43; 1 RCT, n = 262; very low‐quality evidence; Analysis 1.3). The evidence suggests that if disease recurrence at 12 months or less by EEC stage is assumed to be 45% among women with surgery alone, the chance following presurgical medical hormonal suppression would be between 39% and 65%. </p> </section> <section id="CD003678-sec-0069"> <h5 class="title">1.5 Pregnancy rate (dichotomous)</h5> <p><a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> compared pregnancy rate (pregnancies, abortions, and extrauterine pregnancies) for presurgical GnRHas therapy for two years after start of the study (Analysis 1.4). We are uncertain if presurgical medical hormonal suppression improves pregnancy rate compared to surgery alone (RR 1.18, 95% CI 0.97 to 1.45; 1 RCT, n = 262; very low‐quality evidence; Analysis 1.4). The evidence suggests that if pregnancy rate is assumed to be 58% among women with surgery alone, the pregnancy rate following presurgical medical hormonal suppression would be between 53% and 79%. </p> </section> <section id="CD003678-sec-0070"> <h5 class="title">1.6 Ease of surgery, duration of surgery, postsurgical complications</h5> <p>No studies reported ease of surgery, duration of surgery, or postsurgical complications.</p> </section> <section id="CD003678-sec-0071"> <h5 class="title">1.7 Levels of satisfaction of women</h5> <p>No studies reported levels of satisfaction of women participants.</p> </section> <section id="CD003678-sec-0072"> <h5 class="title">1.8 Adverse events</h5> <p>No studies reported serious adverse events. Adverse events are reported in <a href="#CD003678-tbl-0005">Table 2</a>. </p> <div class="table" id="CD003678-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ADEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Withdrawals due to ADEs</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were reported with equal frequency in both groups and were consistent with those published by other investigators. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 withdrawals after randomization from hot flushes and headaches.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperandrogenism 16.7%, weight gain ≥ 3 kg 8.3%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most experienced menopausal symptoms, all became amenorrhoeic.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 withdrawal from unacceptable adverse events.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparable in 3 groups: headache in 10 participants, decreased libido in 9, spotting in 6, water retention in 4, vaginal dryness in 2, depression in 1, acne in 1, insomnia in 1. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 withdrawals from adverse events attributable to OC’s</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not due to ADEs.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidences of uterine bleeding, acne, and weight gain were significant lower in therapy group than control group while incidence of vaginal dryness was significant higher in control group. No differences regarding the incidence of hot flushes, sleep disorder, and headache between 2 groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not due to ADEs.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amenorrhoea in all actively treated, 0 in placebo group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cyclic OC group: 4 did not complete study due to adverse events. Continuous OC group: 4 did not complete study due to adverse events. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cyclic OC group: 8 did not complete study due to adverse events. Continuous OC group: 6 did not complete study due to adverse events. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Menopausal symptoms, spotting, bloating, weight gain, and headache reported, but "well tolerated." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 withdrew from hormonal suppression group due to adverse events.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GnRHas: 7 women experienced hot flushes, vaginal dryness, and reduced libido caused by hypo‐oestrogenism. </p> <p>OC: 4 women experienced breakthrough bleeding, headache, breast tension, nausea, and weight gain. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 in hormonal suppression therapy (GnRHas and OC).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hot flushes (62%), headaches (29%), and dysmenorrhoea (14%) in goserelin group and dysmenorrhoea (33%) in no therapy group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 withdrew from goserelin group due to serious adverse events (only 1 related to therapy)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Menstruation alterations (Amenorrhea, spotting, light bleeding), acne, breast pain, headache, nausea/vomiting, hair loss, mood change, rash. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not due to ADE.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight increase MPA 1.9 kg (SD 1.3), danazol 3.4 kg (SD 2.3), placebo 0.4 kg (SD 2.6); breakthrough bleeding at 6 months: MPA 65%, danazol 56%, placebo 6%; acne at 6 months: danazol 56%, placebo 6%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not due to ADE.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reasons for withdrawals not given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 nausea and vomiting, pain at injection site, vertigo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADE: adverse drug effects; GnRHa: gonadotropin‐releasing hormone agonist; MPA: medroxyprogesterone acetate; OC: oral contraception; SD: standard deviation. </p> </div> </div> </section> </section> <section id="CD003678-sec-0073"> <h4 class="title">2. Postsurgical medical therapy compared with placebo or no medical therapy</h4> <p>(Analysis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis 2.5; <a href="#CD003678-tbl-0004">Table 1</a>) </p> <p>Twenty studies compared postsurgical medical therapy with placebo or no medical therapy (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). </p> <section id="CD003678-sec-0074"> <h5 class="title">2.1 Pain (continuous)</h5> <p>Six trials reported he continuous outcome of pain measured by VAS (<a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a>; <a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>). Meta‐analysis was possible for the continuous outcome, mean VAS score of pelvic pain for 12 months' follow‐up or less, for three studies (<a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>). We are uncertain whether postsurgical medical therapy improves pelvic pain at 12 months compared to placebo (SMD ‐0.79, 95% CI ‐1.02 to ‐0.56; 3 RCTs, n = 340; I<sup>2</sup> = 91%; very low‐quality evidence; Analysis 2.1). A fourth study reported pain after 12 months using a 4‐point scale and presented mean scores without estimates of precision (<a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>). It was not possible to include these data in the meta‐analysis but the estimates are recorded in <a href="#CD003678-tbl-0004">Table 1</a>. </p> <p><a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a> mentioned pain recurrence according to the SF‐36 subscale. There was no evidence of a difference (SMD 0.11, 95% CI ‐0.21 to 0.42; 1 RCT, n = 159; very low‐quality evidence). </p> <p>In the meta‐analysis, two trials reported for the continuous outcome, mean VAS score for dysmenorrhoea and dyspareunia (<a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>). We are uncertain whether postsurgical medical therapy showed a reduction in dysmenorrhoea and dyspareunia at 12 months compared to placebo. These studies show inconsistent effects and considerable statistical heterogeneity (dysmenorrhoea: SMD ‐0.38, 95% CI ‐0.62 to ‐0.14; 2 RCTs, n = 287; I<sup>2</sup> = 78%; very low‐quality evidence; dyspareunia: (SMD ‐0.44, 95% CI ‐0.67 to ‐0.20; 2 RCTs, n = 287; I<sup>2</sup> = 37%; very low‐quality evidence; Analysis 2.1). </p> <p>Two trials presented the change in pain score from the baseline to 12 months after surgery (<a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>). We are uncertain whether postsurgical medical therapy decreased pain scores after 12 months postsurgical, compared to no medical therapy (SMD –0.26, 95% CI –0.60 to 0.09; 2 RCTs, n = 129; very low‐quality evidence; Analysis 2.1). We are uncertain if postsurgical medical therapy leads to a change in dysmenorrhoea (SMD –0.28, 95% CI –0.90 to 0.34; 1 RCT, n = 40; very low‐quality evidence), dyspareunia (SMD –0.13, 95% CI –0.75 to 0.49; 1 RCT, n = 40; very low‐quality evidence), and overall pain (SMD –0.31, 95% CI –0.94 to 0.31; 1 RCT, n = 40; very low‐quality evidence) from baseline to 12 months after surgery, compared to no medical therapy (Analysis 2.1). </p> </section> <section id="CD003678-sec-0075"> <h5 class="title">2.2 Pain recurrence (dichotomous)</h5> <p>Five trials measured pelvic pain recurrence during the first year after surgical treatment (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>). Compared to surgery alone, postsurgical medical therapy may decrease pain recurrence at 12 months or less (RR 0.70, 95% CI 0.52 to 0.94; 5 RCTs, n = 657; I<sup>2</sup> = 0%; low‐quality evidence). </p> <p>The evidence suggests that if pelvic pain recurrence at 12 months or less (dichotomous) is assumed to be 26% among women with surgery alone, the chance following presurgical medical hormonal suppression would be between 13% to 24% (Analysis 2.2). </p> <p>Three trials reported pain recurrence during the second year after surgery (<a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a>; <a href="./references#CD003678-bbs2-0030" title="VercelliniP , FrontinoG , GiorgiOD , AimiG , ZainaB , CrosignaniPG . Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertility and Sterility2003;80(2):305-9. ">Vercellini 2003</a>), but we are uncertain about the effect of postsurgical medical therapy on pain recurrence compared to surgery alone (RR 0.70, 95% CI 0.47 to 1.03; I<sup>2</sup> = 0%; 3 RCTs, n = 312; very low‐quality evidence) (Analysis 2.2). </p> <p>One study reported data on pain persistence or recurrence five years after therapy (<a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>). Due to the wide 95% CIs, we are uncertain if there is a positive effect of postsurgical medical therapy on pain reduction compared to no therapy (RR 0.93, 95% CI 0.53 to 1.66; 1 RCT, n = 54; very low‐quality evidence; Analysis 2.2). Only one trial presented dysmenorrhoea recurrence (RR 0.82, 95% CI 0.50 to 1.35; 1 RCT, n= 285) </p> <p>and dyspareunia recurrence (RR 0.53, 95% CI 0.27 to 1.03; 1 RCT, n = 285) (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>). </p> </section> <section id="CD003678-sec-0076"> <h5 class="title">2.3 Disease recurrence (continuous)</h5> <p>One study reported AFS scores for disease recurrence (<a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>). After 12 months, a second‐look laparoscopy showed a reduction in AFS scores from baseline in all three groups: MPA, danazol, and placebo. There was a mean difference favouring MPA and danazol, when individually compared with placebo. There was no significant difference between the MPA and danazol groups in this respect. The results were inconclusive when mean AFS score were combined (MPA + danazol) and postsurgical medical therapies were compared with placebo (MD –2.29, 95% CI –4.01 to –0.57, 1 RCT, n = 51; very low‐quality evidence; Analysis 2.3). </p> </section> <section id="CD003678-sec-0077"> <h5 class="title">2.4 Disease recurrence (dichotomous)</h5> <p>Disease recurrence, evaluated by gynaecological examination or ultrasonography, was measured at two time points: one year and two years after surgery. Four studies published the results of disease recurrence for 12 months' follow‐up or less (<a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). There may be an decrease of disease recurrence in favour of postsurgical medical therapy, compared to no therapy (RR 0.30, 95% CI 0.17 to 0.54; I<sup>2</sup> = 58%; 4 RCTs, n = 433; low‐quality evidence; Analysis 2.4). This suggest that if the change of disease recurrence following no medical therapy is 17%, the chance following postsurgical medical therapy would be between 3% and 9%. </p> <p>Four studies reported disease recurrence two years after surgery (<a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>). There may be a reduction of disease recurrence in favour of postsurgical hormonal therapy, compared to no postsurgical medical therapy (RR 0.40, 95% CI 0.27 to 0.58; I<sup>2</sup> = 57%; 4 RCTs, n = 571; low‐quality evidence; Analysis 2.4). </p> <p><a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> described distribution of EEC stage, comparing baseline and five months after starting hormonal therapy or five months after primary surgery. There was a reduction of EEC stages in the group with hormonal therapy, but due to this being a single study with wide 95% CIs, the results are inconclusive (RR 0.88, 95% CI 0.67 to 1.15; 1 RCT, n = 285; very low‐quality evidence; Analysis 2.4). </p> </section> <section id="CD003678-sec-0078"> <h5 class="title">2.5 Pregnancy rate (dichotomous)</h5> <p>Eleven studies reported pregnancy (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a>; <a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a>; <a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a>; <a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a>; <a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>; <a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a>; <a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a>). Surgery plus medical therapy probably increases pregnancy rate compared to either surgery plus placebo or no medical therapy (RR 1.19, 95% CI 1.02 to 1.38; 11 RCTs, n = 955; I<sup>2</sup> = 27%; moderate‐quality evidence; Analysis 2.5). This suggests that if the chance of pregnancy following no medical therapy is 34%, the chance following postsurgical medical therapy would be between 35% and 48%. </p> </section> <section id="CD003678-sec-0079"> <h5 class="title">2.6 Ease of surgery, duration of surgery, postsurgical complications</h5> <p>No studies reported ease of surgery, duration of surgery, or postsurgical complications.</p> </section> <section id="CD003678-sec-0080"> <h5 class="title">2.7 Levels of satisfaction of women</h5> <p>One study reported participant satisfaction (<a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a>). There was an increase in participant satisfaction in both active treatment groups, which was statistically significantly greater compared to the placebo group, but there was no difference between the danazol and MPA groups (<a href="#CD003678-tbl-0004">Table 1</a>). </p> </section> <section id="CD003678-sec-0081"> <h5 class="title">2.8 Adverse events</h5> <p>No studies reported serious adverse events. Adverse events are reported in <a href="#CD003678-tbl-0005">Table 2</a>. </p> </section> </section> <section id="CD003678-sec-0082"> <h4 class="title">Sensitivity analysis</h4> <p>Nine studies were at low risk of bias of selection bias (<a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>; <a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a>; <a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>). </p> <p>A sensitivity analysis was only performed for the primary outcomes included in the comparison of postsurgical medical therapy versus no medical therapy. Planned sensitivity analysis was not undertaken for the other comparisons because none of the trials were at low risk of bias. </p> <section id="CD003678-sec-0083"> <h5 class="title">Pain (continuous)</h5> <p>For this sensitivity analysis, three trials reported the continuous outcome of pain, measured by VAS (<a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>; <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>). Meta‐analysis was possible for the continuous outcome, mean VAS score of pelvic pain for 12 months' follow‐up or less, for two studies (<a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a>; <a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a>). The pooled estimate showed a reduction in pelvic pain at 12 months favouring medical therapy compared to placebo (MD –1.18, 95% CI –1.45 to –0.91; I<sup>2</sup> = 14%; 2 RCTs, n = 240; low‐quality evidence). </p> <p><a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a> reported the continuous outcome, mean VAS score for dysmenorrhoea and dyspareunia. Postsurgical medical therapy decreases complaints of dysmenorrhoea or dyspareunia, compared to placebo or no medical therapy (dysmenorrhoea: MD –0.70, 95% CI –1.04 to –0.36; 1 RCT, n = 187; very low‐quality evidence; dyspareunia: MD –0.40, 95% CI –0.76 to –0.04; 1 RCT, n = 187; very low‐quality evidence). </p> <p><a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a> reported the change in pain score from the baseline to 12 months after surgery. It found no difference between postsurgical medical therapy and placebo. <a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a> also presented change in dysmenorrhoea, dyspareunia, and overall pain from baseline to 12 months after surgery, and found no evidence of a difference between medical therapy and placebo. </p> </section> <section id="CD003678-sec-0084"> <h5 class="title">Pain (dichotomous)</h5> <p>Two studies reported pain recurrence during the first year after surgical treatment (<a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a>; <a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a>). The pooled estimate from these trials showed a difference between medical therapy and surgery alone, in favour of postsurgical medical therapy (RR 0.53, 95% CI 0.29 to 0.96; I<sup>2</sup> = 27%; 2 RCTs, n = 250; low‐quality evidence). </p> <p>One trial reported pain recurrence during the second year after surgery (<a href="./references#CD003678-bbs2-0030" title="VercelliniP , FrontinoG , GiorgiOD , AimiG , ZainaB , CrosignaniPG . Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertility and Sterility2003;80(2):305-9. ">Vercellini 2003</a>). There was no evidence of a difference between medical therapy after surgery and surgery alone (RR 0.64, 95% CI 0.39 to 1.05; 1 RCT, n = 155; very low‐quality evidence). </p> </section> <section id="CD003678-sec-0085"> <h5 class="title">Disease recurrence (continuous)</h5> <p>Disease recurrence, evaluated by gynaecological examination or ultrasonography, was measured at two time points: one year and two years after surgery. One study published the results of disease recurrence for 12 months' follow‐up or less (<a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a>). There was a difference in favour of hormonal therapy (RR 0.16, 95% CI 0.07 to 0.38; 1 RCT, n = 137; very low‐quality evidence). </p> <p>A sensitivity analysis was also performed to compare outcomes based on random effects model. A difference in result was only observed in comparison postsurgical medical therapy compared with placebo or no medical therapy for the following outcomes: pelvic pain (MD ‐0.34, 95% CI ‐1.14 to 0.46; I<sup>2</sup> = 94%; 4 RCTs, n= 419, dysmenorrhoea (MD ‐0.14, 95% CI ‐0.96 to 0.69; I<sup>2</sup> = 80%; 3 RCTs, n = 366), and deep dyspareunia (MD ‐0.13, 95% CI ‐0.75 to 0.49; I<sup>2</sup> = 89%; 3 RCTs; n = 366). Nevertheless, we did not consider this difference meaningful due to the very low quality evidence and very high heterogeneity. No difference in result was observed in the other analyses. </p> </section> </section> <section id="CD003678-sec-0086"> <h4 class="title">3. Pre‐ and postsurgical medical therapy compared with placebo or no medical therapy</h4> <p>We found no studies comparing pre‐ and postsurgical medical therapy with placebo or no medical therapy. </p> </section> <section id="CD003678-sec-0087"> <h4 class="title">4. Presurgical medical therapy compared with postsurgical medical therapy</h4> <p>(Analysis 3.1; Analysis 3.2; Analysis 3.3; <a href="#CD003678-tbl-0004">Table 1</a>; <a href="#CD003678-tbl-0005">Table 2</a>) </p> <p>Two studies compared presurgical medical therapy with postsurgical medical therapy (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>). There were too few studies to conduct any planned sensitivity analyses. </p> <section id="CD003678-sec-0088"> <h5 class="title">4.1 Pain (continuous)</h5> <p>No studies reported pain.</p> </section> <section id="CD003678-sec-0089"> <h5 class="title">4.2 Pain recurrence (dichotomous)</h5> <p>Two studies reported pain recurrence (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>; <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>). We are uncertain whether there was a reduction in pelvic pain with presurgical medical therapy after 12 months' follow‐up, compared to postsurgical medical therapy. <a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> showed a difference in favour of postsurgical hormonal therapy (group 3) compared to presurgical hormonal therapy (group 1), for dysmenorrhoea and dyspareunia. <a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a> also compared these two groups for dysmenorrhoea and dyspareunia, but found no differences (Analysis 3.1). </p> <p>We are uncertain if there is a difference in pelvic pain recurrence at 12 months or less (dichotomous) between postsurgical and presurgical medical hormonal suppression therapy (RR 1.40, 95% CI 0.95 to 2.07; I<sup>2</sup> = 2%; 2 RCTs, n = 326; low‐quality evidence). The evidence suggests that if the pelvic pain recurrence at 12 months or less (dichotomous) is assumed to be 20% among women with postsurgical medical hormonal suppression alone, the chance following presurgical medical hormonal suppression would be between 19% and 41% (Analysis 3.1). </p> <p>We are uncertain if there is a difference in dysmenorrhoea recurrence at 12 months or less (dichotomous) between postsurgical and presurgical medical hormonal suppression therapy (RR 1.73, 95% CI 1.09 to 2.74; I<sup>2</sup> = not applicable; 2 RCTs; n = 326; very low‐quality evidence; Analysis 3.1). </p> <p>We are uncertain whether there is a difference in dyspareunia recurrence at 12 months or less (dichotomous) between postsurgical and presurgical medical hormonal suppression therapy (RR 3.08, 95% CI 1.68 to 5.62; I<sup>2</sup> = 0%; 2 RCTs, n = 326; very low‐quality evidence; Analysis 3.1). </p> <p>One study compared postsurgical and presurgical hormonal suppression therapy for pelvic tenderness and pelvic induration at 12 months or less (<a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a>). We are uncertain if there is a difference in pelvic tenderness at 12 months or less (dichotomous) between postsurgical and presurgical medical hormonal suppression therapy (RR 0.95, 95% CI 0.52 to 1.72; 1 RCTs, n = 53; very low‐quality evidence; Analysis 3.1). We are uncertain if there is a difference observed in pelvic induration at 12 months or less (dichotomous) between postsurgical and presurgical medical hormonal suppression therapy (RR 1.63, 95% CI 0.94 to 2.81; 1 RCTs, n = 53; very low‐quality evidence; Analysis 3.1). </p> </section> <section id="CD003678-sec-0090"> <h5 class="title">4.3 Disease recurrence (continuous)</h5> <p><a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a> reported that the presurgical nafarelin group had lower global AFS scores, adhesion scores and 'endometriosis scores' compared to the postsurgical nafarelin group, but data were presented in a form that was not suitable for inclusion in a forest plot so the data are recorded in <a href="#CD003678-tbl-0004">Table 1</a>. </p> </section> <section id="CD003678-sec-0091"> <h5 class="title">4.4 Disease recurrence (dichotomous)</h5> <p>One study compared postsurgical and presurgical hormonal suppression therapy for disease recurrence using EEC staging (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>). </p> <p>We are uncertain if there is a difference in disease recurrence at 12 months or less (EEC stage) between postsurgical and presurgical medical hormonal suppression therapy (RR 1.26, 95% CI 0.97 to 1.65; 1 RCT, n = 273; very low‐quality evidence). The evidence suggests that if the disease recurrence at 12 months or less (EEC stage) is assumed to be 40% among women with postsurgical medical hormonal suppression alone, the chance following presurgical medical hormonal suppression would be between 39% and 66% (Analysis 3.2). </p> </section> <section id="CD003678-sec-0092"> <h5 class="title">4.5 Pregnancy rate (dichotomous)</h5> <p>One study reported pregnancy rate (<a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a>). We are uncertain if pregnancy rate is improved with presurgical medical hormonal suppression therapy compared to postsurgical medical hormonal suppression therapy (RR 1.08, 95% CI 0.90 to 1.30; 1 RCT, n = 273; very low‐quality evidence). </p> <p>The evidence suggests that if the pregnancy rate is assumed to be 60% among women with postsurgical medical hormonal suppression alone, the chance following presurgical medical hormonal suppression would be between 54% and 78%. </p> <p>(Analysis 3.3).</p> </section> <section id="CD003678-sec-0093"> <h5 class="title">4.6 Ease of surgery, duration of surgery, postsurgical complications</h5> <p>No studies reported ease of surgery, duration of surgery, postsurgical complications.</p> </section> <section id="CD003678-sec-0094"> <h5 class="title">4.7 Levels of satisfaction of women</h5> <p>No studies reported levels of satisfaction of women participants.</p> </section> <section id="CD003678-sec-0095"> <h5 class="title">4.8 Adverse events</h5> <p>No reported serious adverse events. Adverse events are reported in <a href="#CD003678-tbl-0005">Table 2</a>. </p> </section> </section> <section id="CD003678-sec-0096"> <h4 class="title">5. Postsurgical medical therapy compared with pre‐ and postsurgical medical therapy</h4> <p>We found no studies comparing postsurgical medical therapy with pre‐ and postsurgical medical therapy. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003678-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003678-sec-0097"></div> <section id="CD003678-sec-0098"> <h3 class="title" id="CD003678-sec-0098">Summary of main results</h3> <p>There is insufficient evidence to support the view that medical therapy for hormonal suppression of endometriosis prior to surgery is more effective than surgery alone. Two studies compared presurgical medical therapy with surgery alone. We are uncertain if AFS scores were improved in the medical therapy group, because of the very low‐quality evidence. There was uncertainty that disease recurrence at 12 months or less, measured by EEC stage, was improved after presurgical hormonal therapy (very low‐quality evidence). Results were inconclusive regarding pregnancy rate, with very low‐quality evidence. A sensitivity analysis of the data from these studies was not possible, as only one study reported each outcome. </p> <p>There was uncertainty that postsurgical hormonal suppression of endometriosis compared to surgery alone (either no medical therapy or placebo) showed a reduction in pain after 12 months (pelvic pain, dysmenorrhoea, and dyspareunia) measured by VAS score (very low‐quality evidence). Pain recurrence at 12 months or less (dichotomous) showed inconclusive data about the effect of postsurgical medical therapy compared to no medical therapy or placebo (very low‐quality evidence). There may be a benefit for disease recurrence (AFS scores), when postsurgical medical therapy is compared to no medical therapy (low‐quality evidence). The meta‐analysis showed that postsurgical medical therapy group probably improves pregnancy rate, compared to no medical therapy, with moderate‐quality evidence. A sensitivity analysis was conducted for the primary outcomes. Nine studies were at low risk of bias of selection bias. For this sensitivity analysis, for the continuous outcome of pain, measured by VAS, the pooled estimate may have reduced pelvic pain at 12 months favouring medical therapy compared to placebo (low‐quality evidence). There was inconclusive evidence regarding the effects of postsurgical medical therapy compared to no medical therapy, for dysmenorrhoea and dyspareunia (very low‐quality evidence). Disease recurrence may show an improvement in favour of postsurgical hormonal therapy, compared to no medical therapy (low‐quality evidence). The sensitivity analysis did not change the conclusion of the results. </p> <p>There were no trials that compared hormonal suppression of endometriosis before and after surgery with surgery alone. </p> <p>There may be some improvement in favour of postsurgery hormonal suppression for dysmenorrhoea and dyspareunia compared to presurgery hormonal suppression (low‐quality evidence). We are uncertain about the effect of postsurgical medical therapy compared to presurgical medical therapy on pelvic pain recurrence. Results were inconclusive regarding pregnancy rate when presurgical hormonal therapy was compared to postsurgical hormonal therapy. All outcomes, except pelvic pain recurrence at 12 months or less, were of very low‐quality evidence, related to a single study included in the analysis. Pelvic pain recurrence at 12 months or less was of low‐quality evidence. </p> <p>There were no trials that compared hormonal suppression of endometriosis after surgery with before and after surgery </p> <p>In summary, data included were inconsistent about the use of medical therapy after surgery for endometriosis, regarding reduction and recurrence of pain. Recurrence of endometriosis may also decrease with postsurgical hormonal therapy, but again, data were inconsistent and of low‐ to moderate‐quality evidence. When used prior to surgery, medical therapy was inconclusive about the effect on cyst size and the effect on AFS scores was conflicting. There is inconclusive evidence that medical therapy pre‐ or postsurgery improves pregnancy rates. No conclusions can be drawn with respect to the outcomes of facilitating surgery, duration of surgery, postsurgical complications, or levels of satisfaction of participants from the trials included in this review. Adverse effects were described but not quantified, so no direct comparisons between the included trials were possible. </p> </section> <section id="CD003678-sec-0099"> <h3 class="title" id="CD003678-sec-0099">Overall completeness and applicability of evidence</h3> <p>Given the thorough search strategy and clear inclusion and exclusion criteria, this review provides a comprehensive overview of the current scientific evidence pertaining to the timing of medical hormonal suppression therapy for women undergoing surgery for endometriosis. All 25 studies included in systematic review were also included in meta‐analyses. All women of reproductive age, as defined by authors of included studies, were included in review without any additional age limitation. The review presented five different comparisons based on variable potential timing of administration of medical therapy. Most of the eligible studies compared medical therapy after surgery with placebo or no medical therapy and the evidence answers the review question adequately and is generally in line with current practice. However, there were very few eligible studies that compared presurgical medical therapy with placebo or no medical therapy or postsurgical medical therapy; and none compared pre‐ and postsurgical medical therapy with placebo or no medical therapy or postsurgical medical therapy resulting in inadequate answers for the review questions. </p> </section> <section id="CD003678-sec-0100"> <h3 class="title" id="CD003678-sec-0100">Quality of the evidence</h3> <p>We prepared 'Summary of findings' tables using GRADEpro and Cochrane methods.</p> <p>We judged the evidence for the comparisons 'presurgical medical therapy compared with placebo or no medical therapy' and 'presurgical medical therapy compared with postsurgical medical therapy' as very low quality. The comparison 'postsurgical medical therapy compared with placebo or no medical therapy' was moderate‐ to very low‐quality evidence, depending on the outcome measurement. </p> <p>A strength of this review is that all the included studies involved women with laparoscopically diagnosed endometriosis and laparoscopic assessment of the extent of the endometriosis. Weaknesses of this review are that the included studies were small and many were at risk of bias. Several additional studies were identified on this review, and even though there was a spread of different times at which a range of different outcomes were measured, the additional studies allowed for some studies to be combined in meta‐analysis for some outcomes. </p> <p>The quality of evidence for the pregnancy rate or disease recurrence at 12 months or less among the studies comparing postsurgical medical therapy with surgery alone was moderate. Magnitude of risk reduction of disease recurrence was large with moderate variability among studies (I<sup>2</sup> = 58%), but in case of pregnancy rate the magnitude of effect size was modest with relatively large variability between studies (I<sup>2</sup> = 24%). Though these results can support the practice of postsurgical medical therapy, additional methodologically robust studies measuring these outcomes can help in improving the quality of evidence. </p> <p>The quality of evidence for most of the other outcomes reviewed was either very low or low, primarily due to few studies with small sizes reporting each outcome or poorly reported methods. And as result this evidence may not be considered sufficient to recommend practice change. </p> </section> <section id="CD003678-sec-0101"> <h3 class="title" id="CD003678-sec-0101">Potential biases in the review process</h3> <p>Potential biases in the review process were minimized by searching published and unpublished literature from a variety of sources with no restrictions on date of publication or language. At least two review authors independently extracted data and conducted the risk of bias assessment. </p> <p>The main problem remains is that the small number of trials per outcome across multiple comparisons makes meta‐analysis difficult. The publications included spanned over 31 years (from 1987 to 2018) during which time the methods and data reporting practices have changed significantly. Attempts to contact authors for older publications were often unsuccessful, resulting in poor scoring in risk of bias assessment due to inadequate information. Inaccessibility to useful information available with these authors, but not included in papers, might have also limited the meta‐analysis. </p> </section> <section id="CD003678-sec-0102"> <h3 class="title" id="CD003678-sec-0102">Agreements and disagreements with other studies or reviews</h3> <p>Several systematic reviews have been conducted to investigate individual or grouped hormonal suppression therapies in management of endometriosis. As a result, postsurgical therapy with either OCP or GnRHas have become standard care in women with endometriosis, as recommended by the guideline of the European Society of Human Reproduction and Embryology (ESHRE) (<a href="./references#CD003678-bbs2-0042" title="DunselmanGA , VermeulenN , BeckerC , Calhaz-JorgeC , D'HoogheT , De BieB , et al. ESHRE guideline: management of women with endometriosis. Human Reproduction2014;3:400-12.">Dunselman 2014</a>). presurgical hormonal therapy is less‐common practice, and has not been recommended by the ESHRE guideline. </p> <p>However, in our review of the literature, we identified no other review pertaining to the timing of medical management in women undergoing surgery for endometriosis. We believe this updated review will contribute to the better management of endometriosis by practicing gynaecologists regarding best time to use these medicines. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003678-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram." data-id="CD003678-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003678-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003678-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Presurgical medical therapy compared with placebo or no medical therapy, Outcome 1: Pain recurrence (dichotomous)" data-id="CD003678-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Presurgical medical therapy compared with placebo or no medical therapy, Outcome 1: Pain recurrence (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Presurgical medical therapy compared with placebo or no medical therapy, Outcome 2: Disease recurrence (continuous)" data-id="CD003678-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Presurgical medical therapy compared with placebo or no medical therapy, Outcome 2: Disease recurrence (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Presurgical medical therapy compared with placebo or no medical therapy, Outcome 3: Disease recurrence (dichotomous)" data-id="CD003678-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Presurgical medical therapy compared with placebo or no medical therapy, Outcome 3: Disease recurrence (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Presurgical medical therapy compared with placebo or no medical therapy, Outcome 4: Pregnancy rate (dichotomous)" data-id="CD003678-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Presurgical medical therapy compared with placebo or no medical therapy, Outcome 4: Pregnancy rate (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Postsurgical medical therapy compared with placebo or no medical therapy, Outcome 1: Pain (continuous)" data-id="CD003678-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Postsurgical medical therapy compared with placebo or no medical therapy, Outcome 1: Pain (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Postsurgical medical therapy compared with placebo or no medical therapy, Outcome 2: Pain recurrence (dichotomous)" data-id="CD003678-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Postsurgical medical therapy compared with placebo or no medical therapy, Outcome 2: Pain recurrence (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Postsurgical medical therapy compared with placebo or no medical therapy, Outcome 3: Disease recurrence (continuous)" data-id="CD003678-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Postsurgical medical therapy compared with placebo or no medical therapy, Outcome 3: Disease recurrence (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Postsurgical medical therapy compared with placebo or no medical therapy, Outcome 4: Disease recurrence (dichotomous)" data-id="CD003678-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Postsurgical medical therapy compared with placebo or no medical therapy, Outcome 4: Disease recurrence (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Postsurgical medical therapy compared with placebo or no medical therapy, Outcome 5: Pregnancy rate (dichotomous)" data-id="CD003678-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Postsurgical medical therapy compared with placebo or no medical therapy, Outcome 5: Pregnancy rate (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Presurgical medical therapy compared with postsurgical medical therapy, Outcome 1: Pain recurrence (dichotomous)" data-id="CD003678-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Presurgical medical therapy compared with postsurgical medical therapy, Outcome 1: Pain recurrence (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Presurgical medical therapy compared with postsurgical medical therapy, Outcome 2: Disease recurrence (dichotomous)" data-id="CD003678-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Presurgical medical therapy compared with postsurgical medical therapy, Outcome 2: Disease recurrence (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003678-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/urn:x-wiley:14651858:media:CD003678:CD003678-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Presurgical medical therapy compared with postsurgical medical therapy, Outcome 3: Pregnancy rate (dichotomous)" data-id="CD003678-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_t/tCD003678-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Presurgical medical therapy compared with postsurgical medical therapy, Outcome 3: Pregnancy rate (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/media/CDSR/CD003678/image_n/nCD003678-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003678-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Presurgical medical therapy compared with placebo or no medical therapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Presurgical medical therapy compared with placebo or no medical therapy for endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women having endometriosis surgery </p> <p><b>Intervention:</b> presurgical medical therapy </p> <p><b>Comparison:</b> placebo or no medical therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no medical therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Presurgical medical therapies</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> (continuous) </p> <p>Pelvic pain ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain recurrence</b> (dichotomous) </p> <p>Pain recurrence ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>265 per 1000</b><br/>(174 to 400) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/>(0.72 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence at 3 months</b> – total (AFS score) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean recurrence – AFS score – total AFS in the control groups was 44.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean recurrence – AFS score – total AFS in the intervention groups was<br/><b>9.6 lower</b><br/>(11.42 to 7.78 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence ≤ 12 months</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence ≤ 12 months (EEC stage)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>453 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>502 per 1000</b> </p> <p>(389 to 647)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> (0.86 to 1.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy rate</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>547 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>646 per 1000</b><br/>(531 to 794) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b><br/>(0.97 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AFS:</b> American Fertility Society; <b>CI:</b> confidence interval; <b>EEC:</b> Endoscopic Endometriosis Classification; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for serious risk of bias – no blinding and trial lacked details on allocation concealment.<br/><sup>b</sup>Downgraded twice for very serious imprecision – evidence based on a single trial, wide confidence interval, small number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Presurgical medical therapy compared with placebo or no medical therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003678-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Postsurgical medical therapy compared with placebo or no medical therapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Postsurgical medical therapy compared with placebo or no medical therapy for endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women having endometriosis surgery </p> <p><b>Intervention:</b> postsurgical medical therapy </p> <p><b>Comparison:</b> placebo or no medical therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no medical therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Postsurgical medical therapies</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> (continuous) </p> <p>Pelvic pain ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pelvic pain score ≤ 12 months in the ranged across control groups from 0.35 to 7 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pelvic pain score ≤ 12 months in the intervention groups was<br/><b>0.79 lower</b><br/>(1.02 to 0.56 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain recurrence</b> (dichotomous) </p> <p>Pain recurrence ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>255 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> </p> <p>(132 to 239)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b><br/>(0.52 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>657<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence at 12 months</b> – <b>total (AFS score)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean recurrence – AFS score – total AFS in the control groups was 3.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean recurrence – AFS score – total AFS in the intervention groups was<br/><b>2.29 lower</b><br/>(4.01 to 0.57 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence ≤ 12 months</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> </p> <p>(29 to 92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.30</b><br/>(0.17 to 0.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence</b> </p> <p><b>≤ 12 months (EEC stage)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>453 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>398 per 1000</b> </p> <p>(303 to 520)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> (0.67 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy rate</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>409 per 1000</b> </p> <p>(351 to 475)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b><br/>(1.02 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>955</p> <p>(11 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AFS:</b> American Fertility Society; <b>CI:</b> confidence interval; <b>EEC:</b> Endoscopic Endometriosis Classification; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for risk of bias – there are inadequate details on blinding and attrition.<br/><sup>b</sup>Downgraded twice for very serious inconsistency – considerable heterogeneity.<br/><sup>c</sup>Downgraded once for imprecision – small number of events </p> <p><sup>d</sup>Downgraded twice for very serious imprecision – small number of events/evidence is based on a single study.<br/><sup>e</sup>Downgraded once for risk of bias – the trial lacked details on allocation concealment and randomization..<br/><sup>f</sup>Downgraded once for inconsistency – considerable heterogeneity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Postsurgical medical therapy compared with placebo or no medical therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003678-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Presurgical medical therapy compared with postsurgical medical therapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Presurgical medical therapy compared with postsurgical medical therapy for endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women having endometriosis surgery </p> <p><b>Intervention:</b> presurgical medical therapy </p> <p><b>Comparison:</b> postsurgical medical therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Postsurgical medical therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Presurgical medical therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> (continuous) </p> <p>Pelvic pain ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain recurrence</b> (dichotomous) </p> <p>Pain recurrence ≤ 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>279 per 1000</b> </p> <p>(189 to 412)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b><br/>(0.95 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence at 12 months</b> –<b>total (AFS score)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence ≤ 12 months</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported on this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease recurrence ≤ 12 months (EEC stage)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>399 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>502 per 1000</b> </p> <p>(387 to 658)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b><br/>(0.97 to 1.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pregnancy rate</b> (dichotomous) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>601 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>649 per 1000</b> </p> <p>(541 to 782)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/>(0.90 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AFS:</b> American Fertility Society; <b>CI:</b> confidence interval; <b>EEC:</b> Endoscopic Endometriosis Classification; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for serious risk of bias – no blinding and trial lacked details on allocation concealment.<br/><br/><sup>b</sup>Downgraded twice for very serious imprecision – evidence based on a single trial, wide confidence interval, and small number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Presurgical medical therapy compared with postsurgical medical therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003678-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Descriptive data for trials not included in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Conclusion</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical vs no treatment, 2 groups (A = complete excision, B = incomplete excision, 1 = no therapy, 2 = GnRHas). 1A vs 2A </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Differences in participant's quality of life by SF‐36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P &lt; 0.001) for general health, physical function, and vitality after 12 months of complete excision vs complete excision + GnRHas. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical vs no therapy, 2 groups (A = complete excision, B = incomplete excision, 1 = no therapy, 2 = GnRHas). 1A 12 months' follow‐up vs baseline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P &lt; 0.001) for general health, physical function, and vitality 12 months' follow‐up vs baseline for complete excision. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical vs no therapy, 2 groups (A = complete excision, B = incomplete excision, 1 = no therapy, 2 = GnRHas). 2A 12 months' follow‐up vs baseline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P &lt; 0.001) for general health, physical function, and vitality 12 months' follow‐up vs baseline for complete excision + GnRHas. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Presurgical vs postsurgical GnRHa (nafarelin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AFS scores – total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total AFS score after 6 months was 0 in presurgery group and 6 in postsurgery group (P = 0.007); no SD or SE given and not calculable. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AFS scores – adhesion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adhesion AFS score after 6 months was 0 in presurgery group and 2 in postsurgery group (P = 0.007), no SD or SE given and not calculable. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AFS scores – implant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Implant AFS score after 6 months was 0 in presurgery group and 4 in postsurgery group (P = 0.05), no SD or SE given and not calculable. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ease of surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery was easy in 56% of participants with GnRHa therapy presurgery compared to 35.7% in the postsurgery group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presurgical GnRHa (goserelin) vs no medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean endometrioma size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favouring goserelin: mean difference –1.81 cm (95% confidence interval –2.05 to 1.57).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical vs no therapy, GnRHas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total effective rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant higher total effective rate compared to control group in favour of GnRHas group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical vs no medical therapy (cyclic and continuous OC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative pain‐free interval</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87/187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant higher in continuous users vs cyclic (P &lt; 0.0005) and in cyclic vs non‐users (P = 0.01) 18 months postsurgical. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Presurgical GnRHa (goserelin) vs no medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in endometrioma size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favouring goserelin: adjusted mean difference –1.25 cm (95% confidence interval –2.42 to –0.08). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete excision of cyst</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference. 13/21 (72%) in GnRHa group and 16/27 (73%) in no medical therapy group had cysts completely excised at surgery. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of residual cysts at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favours goserelin. 2/21 (10%) in GnRHa and 4/27 (15%) in no medical treatment had recurrence of residual cysts. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean rAFS scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference. 41.7 in GnRHa group and 42.5 in no medical treatment group (no SD given).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MPA vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain scores after 12 months assessed with 4‐point scales; 1.8 in MPA group and 4.4 in placebo group; "significant difference." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danazol vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain scores after 12 months assessed with 4‐point scales; 2.5 in danazol group and 4.4 in placebo group; "significant difference." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MPA vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant satisfaction achieved in 84% in MPA group and 24% in placebo group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danazol vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant satisfaction achieved in 84% in danazol group and 24% in placebo group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical leuprolide/danazol vs no therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative pregnancy rate at 12 months after clomiphene stimulation in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference; 56.7% in leuprolide/danazol group and 54.5% in no therapy group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postsurgical gestrinone vs no medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease recurrence at 6–30 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Favoured medical therapy; 1/19 in gestrinone group and 4/13 in no medical therapy group (P &lt; 0.05). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Postsurgical triptorelin acetate vs no medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total effective rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant higher total effective rate in triptorelin group vs control group (P = 0.009). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levels of E<sub>2</sub>, LH, and FSH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Levels were significantly lower in the triptorelin acetate group than in control group (P &lt; 0.001). </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>AFS: American Fertility Society; FSH: follicle‐stimulating hormone; GnRHa: gonadotropin‐releasing hormone agonist; LH: luteinizing hormone; MPA: medroxyprogesterone acetate; n: number of participants; SD: standard deviation; SE: standard error; SF‐36: 36‐item Short Form. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Descriptive data for trials not included in the meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003678-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ADEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Withdrawals due to ADEs</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0001" title="AlkatoutI , MettlerL , BetetaC , HedderichJ , JonatW , SchollmeyerT , et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. Journal of Minimally Invasive Gynaecology2013;20(4):473-81. ">Alkatout 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0002" title="AngioniS , PontisA , DessoleM , SuricoD , De Cicco NardoneC , MelisI . Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Archives of Gynecology and Obstetrics2015;291:363-70. ">Angioni 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0003" title="AudebertA , DescampsP , MarretH , Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study. Obstetrics and Gynecology1998;79:145-8. ">Audebert 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were reported with equal frequency in both groups and were consistent with those published by other investigators. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 withdrawals after randomization from hot flushes and headaches.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0004" title="BianchiS , BusaccaM , AgnoliB , CandianiM , CaliaC , VignaliM . Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Human Reproduction1999;14(5):1335-7. ">Bianchi 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperandrogenism 16.7%, weight gain ≥ 3 kg 8.3%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0005" title="BusaccaM , SomiglianaE , BianchiS , MarinisSD , CaliaC , CandianiM , et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Human Reproduction2001;16(11):2399-402. ">Busacca 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most experienced menopausal symptoms, all became amenorrhoeic.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 withdrawal from unacceptable adverse events.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0006" title="CucinellaG , GraneseR , CalagnaG , SvelatoA , SaittaS , TonniG , et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?Archives of Gynecology and Obstetrics2013;288:821-7. ">Cucinella 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparable in 3 groups: headache in 10 participants, decreased libido in 9, spotting in 6, water retention in 4, vaginal dryness in 2, depression in 1, acne in 1, insomnia in 1. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 withdrawals from adverse events attributable to OC’s</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0007" title="DonnezJ , AnafV , NisolleM , Clerckx-BraunF , GillerotS , Casanas-RouxF . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertility and Sterility1994;62(1):63-6. ">Donnez 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0008" title="HornsteinMD , HemmingsR , YuzpeAA , HeinrichsWL . Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertility and Sterility1997;68(5):860-4. ">Hornstein 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not due to ADEs.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0009" title="HuangC , WuM , LiuZ , ShiH , HanY , SongX . Clinical efficacy and safety of gonadotropin-releasing hormone agonist combined with laparoscopic surgery in the treatment of endometriosis. International Journal of Clinical and Experimental Medicine2018;11:4132-7. ">Huang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidences of uterine bleeding, acne, and weight gain were significant lower in therapy group than control group while incidence of vaginal dryness was significant higher in control group. No differences regarding the incidence of hot flushes, sleep disorder, and headache between 2 groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0010" title="LoverroG , SantilloV , PansiniMV , LorussoF , DepaloR , SelvaggiL . Are GnRH agonists helpful in the therapy of endometriosis after surgical treatment?Human Reproduction2001;16 Suppl(1):96. ">Loverro 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0011" title="LoverroG , CarrieroC , RossiAC , PutignanoG , NicolardiV , SelvaggiL . A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III–IV endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;136(2):194-8. ">Loverro 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0012" title="MuziiL , MaranaR , CaruanaP , CatalanoGF , MarguttiF , PaniciPB . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology2000;183(3):588-92. ">Muzii 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not due to ADEs.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0013" title="ParazziniF , FedeleL , BusaccaM , FalsettiL , PellegriniS , VenturiniPL , et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. American Journal of Obstetrics and Gynecology1994;171:1205-7. ">Parazzini 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amenorrhoea in all actively treated, 0 in placebo group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0014" title="RickesD , NickelI , KropfS , KleinsteinJ . Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertility and Sterility2002;78:757-62. ">Rickes 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0015" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , MontanariG , KeramydaA , et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertility and Sterility2010;93:52-6. ">Seracchioli 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cyclic OC group: 4 did not complete study due to adverse events. Continuous OC group: 4 did not complete study due to adverse events. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0016" title="SeracchioliR , MabroukM , FrascàC , ManuzziL , SavelliL , VenturoliS . Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertility and Sterility2010;94:464-71. ">Seracchioli 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cyclic OC group: 8 did not complete study due to adverse events. Continuous OC group: 6 did not complete study due to adverse events. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0017" title="SestiF , PietropolliA , CapozzoloT , BroccoliP , PierangeliS , BolleaMR , et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertility and Sterility2007;88(6):1541-7. ">Sesti 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Menopausal symptoms, spotting, bloating, weight gain, and headache reported, but "well tolerated." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 withdrew from hormonal suppression group due to adverse events.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0018" title="SestiF , CapozzoloT , PietropolliA , MarzialiM , BolleaMR , PiccioneE . Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. European Journal of Obstetrics and Gynaecology and Reproductive Biology2009;147:72-7. ">Sesti 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GnRHas: 7 women experienced hot flushes, vaginal dryness, and reduced libido caused by hypo‐oestrogenism. </p> <p>OC: 4 women experienced breakthrough bleeding, headache, breast tension, nausea, and weight gain. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 in hormonal suppression therapy (GnRHas and OC).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0019" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10:151-7. ">Shaw 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hot flushes (62%), headaches (29%), and dysmenorrhoea (14%) in goserelin group and dysmenorrhoea (33%) in no therapy group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 withdrew from goserelin group due to serious adverse events (only 1 related to therapy)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0020" title="TanmahasamutP , SaejongR , RattanachaiyanontM , AngsuwathanaS , TechatraisakK , Sanga-areekulN . Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology2017;33:534-9. ">Tanmahasamut 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Menstruation alterations (Amenorrhea, spotting, light bleeding), acne, breast pain, headache, nausea/vomiting, hair loss, mood change, rash. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not due to ADE.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0021" title="TelimaaS , RonnbergL , KauppilaA . Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecological Endocrinology1987;1(4):363-71. ">Telimaa 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight increase MPA 1.9 kg (SD 1.3), danazol 3.4 kg (SD 2.3), placebo 0.4 kg (SD 2.6); breakthrough bleeding at 6 months: MPA 65%, danazol 56%, placebo 6%; acne at 6 months: danazol 56%, placebo 6%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not due to ADE.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0022" title="Tsai Y-L, Hwang J-L, Loo T-C, Cheng W-C, ChuangJ , Seow K-M. Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. Journal of Reproductive Medicine2004;49(12):955-9. ">Tsai 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reasons for withdrawals not given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0023" title="VercelliniP , CrosignaniPG , FadiniR , RadiciE , BelloniC , SismondiP . A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. British Journal of Obstetrics and Gynaecology1999;106:672-7. ">Vercellini 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0024" title="YangD , MaW , QuF , MAB . Comparative study on the efficiency of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chinese Journal of Integrative Medicine2006;12(3):218-20. ">Yang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not described.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003678-bbs2-0025" title="YangY , ZhuW , ChenS , ZhangG , ChenM , ZhuangY . Laparoscopic surgery combined with GnRH agonist in endometriosis. Journal of the College of Physicians and Surgeons Pakistan2018;29:313-6. ">Yang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 nausea and vomiting, pain at injection site, vertigo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ADE: adverse drug effects; GnRHa: gonadotropin‐releasing hormone agonist; MPA: medroxyprogesterone acetate; OC: oral contraception; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/full#CD003678-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003678-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Presurgical medical therapy compared with placebo or no medical therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Pain recurrence (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Pain recurrence ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.72, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Dysmenorrhoea recurrence ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.92, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Dyspareunia recurrence ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.88, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Disease recurrence (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Disease recurrence at 3 months – total (AFS score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.60 [‐11.42, ‐7.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Disease recurrence at 3 months – implant (AFS score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.70 [‐10.67, ‐6.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Disease recurrence at 3 months – adhesion (AFS score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐3.42, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Disease recurrence (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Disease recurrence ≤ 12 months (EEC stage)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.86, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Pregnancy rate (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Presurgical medical therapy compared with placebo or no medical therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003678-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Postsurgical medical therapy compared with placebo or no medical therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Pain (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Pelvic pain ≤ 12 months (visual analogue scale (VAS))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.79 [‐1.02, ‐0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Dysmenorrhoea ≤ 12 months (VAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.62, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Dyspareunia ≤ 12 months (VAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐0.67, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Pain ≤ 12 months (36‐item Short Form (SF‐36) pain score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.21, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 Change in pelvic pain score ≤ 12 months (VAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.60, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.6 Change in dysmenorrhea score ≤ 12 months (VAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.90, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.7 Change in dyspareunia score ≤ 12 months (VAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.75, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.8 Change in overall pain score ≤ 12 months (VAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.94, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Pain recurrence (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Pain recurrence ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Pain recurrence 13–24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.47, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Pain persistence/recurrence at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.53, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Dysmenorrhoea recurrence ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.50, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 Dyspareunia recurrence ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.27, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Disease recurrence (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Disease recurrence at 12 months – total (American Fertility Society (AFS) score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.29 [‐4.01, ‐0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Disease recurrence (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Disease recurrence ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.17, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Disease recurrence 13–24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.27, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Disease recurrence ≤ 12 months (Endoscopic Endometriosis Classification (EEC) stage) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.67, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Pregnancy rate (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.02, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Postsurgical medical therapy compared with placebo or no medical therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003678-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Presurgical medical therapy compared with postsurgical medical therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Pain recurrence (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Dysmenorrhoea recurrence ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.09, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Dyspareunia recurrence ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [1.68, 5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Pelvic pain recurrence ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.95, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Pelvic tenderness ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.52, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 Pelvic induration ≤ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.94, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Disease recurrence (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Disease recurrence ≤ 12 months (Endoscopic Endometriosis Classification (EEC) stage) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.97, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Pregnancy rate (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Presurgical medical therapy compared with postsurgical medical therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003678.pub3/references#CD003678-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003678.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003678-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003678-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003678-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD003678-note-0013">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD003678-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003678-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD003678-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003678-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003678\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003678\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003678\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003678\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003678\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6nHUP32m&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003678.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003678.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003678.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003678.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003678.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717784274"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003678.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717784278"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003678.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc05fce12936b',t:'MTc0MDcxNzc4NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 